<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">60999</article-id><article-id pub-id-type="doi">10.7554/eLife.60999</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Epidemiology and Global Health</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group></article-categories><title-group><article-title>Improved lipidomic profile mediates the effects of adherence to healthy lifestyles on coronary heart disease</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-201218"><name><surname>Si</surname><given-names>Jiahui</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-201219"><name><surname>Li</surname><given-names>Jiachen</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-201220"><name><surname>Yu</surname><given-names>Canqing</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-201221"><name><surname>Guo</surname><given-names>Yu</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-201222"><name><surname>Bian</surname><given-names>Zheng</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-188566"><name><surname>Millwood</surname><given-names>Iona</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-201223"><name><surname>Yang</surname><given-names>Ling</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-191978"><name><surname>Walters</surname><given-names>Robin</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-201224"><name><surname>Chen</surname><given-names>Yiping</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-201225"><name><surname>Du</surname><given-names>Huaidong</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-201226"><name><surname>Yin</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-201227"><name><surname>Chen</surname><given-names>Jianwei</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-201228"><name><surname>Chen</surname><given-names>Junshi</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-201229"><name><surname>Chen</surname><given-names>Zhengming</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-201230"><name><surname>Li</surname><given-names>Liming</given-names></name><email>lmleeph@vip.163.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-201231"><name><surname>Liang</surname><given-names>Liming</given-names></name><email>lliang@hsph.harvard.edu</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-197410"><name><surname>Lv</surname><given-names>Jun</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7916-3870</contrib-id><email>epi.lvjun@vip.163.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution>Departments of Epidemiology and Biostatistics, Harvard T.H. Chan School of Public Health</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Peking University Institute of Public Health &amp; Emergency Preparedness</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff4"><label>4</label><institution>Chinese Academy of Medical Sciences</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff5"><label>5</label><institution>Medical Research Council Population Health Research Unit at the University of Oxford</institution><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff6"><label>6</label><institution>Clinical Trial Service Unit &amp; Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford</institution><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff7"><label>7</label><institution>NCDs Prevention and Control Department, Hunan Center for Disease Control &amp; Prevention</institution><addr-line><named-content content-type="city">Changsha</named-content></addr-line><country>China</country></aff><aff id="aff8"><label>8</label><institution>Liuyang Center for Disease Control &amp; Prevention, Liuyang</institution><addr-line><named-content content-type="city">Hunan</named-content></addr-line><country>China</country></aff><aff id="aff9"><label>9</label><institution>China National Center for Food Safety Risk Assessment</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff10"><label>10</label><institution>Key Laboratory of Molecular Cardiovascular Sciences (Peking University), Ministry of Education</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Janus</surname><given-names>Edward D</given-names></name><role>Reviewing Editor</role><aff><institution>University of Melbourne</institution><country>Australia</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Barton</surname><given-names>Matthias</given-names></name><role>Senior Editor</role><aff><institution>University of Zurich</institution><country>Switzerland</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>09</day><month>02</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e60999</elocation-id><history><date date-type="received" iso-8601-date="2020-07-13"><day>13</day><month>07</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2021-01-20"><day>20</day><month>01</month><year>2021</year></date></history><permissions><copyright-statement>Â© 2021, Si et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Si et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-60999-v1.pdf"/><abstract><p>Adherence to healthy lifestyles is associated with reduced risk of coronary heart disease (CHD), but uncertainty persists about the underlying lipid pathway. In a caseâcontrol study of 4681 participants nested in the prospective China Kadoorie Biobank, 61 lipidomic markers in baseline plasma were measured by targeted nuclear magnetic resonance spectroscopy. Baseline lifestyles included smoking, alcohol consumption, dietary habit, physical activity, and adiposity levels. Genetic instrument was used to mimic the lipid-lowering effect of statins. We found that 35 lipid metabolites showed statistically significant mediation effects in the pathway from healthy lifestyles to CHD reduction, including very low-density lipoprotein (VLDL) particles and their cholesterol, large-sized high-density lipoprotein (HDL) particle and its cholesterol, and triglyceride in almost all lipoprotein subfractions. The statins genetic score was associated with reduced intermediate- and low-density lipoprotein, but weak or no association with VLDL and HDL. Lifestyle interventions and statins may improve different components of the lipid profile.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>coronary heart disease</kwd><kwd>lifestyle</kwd><kwd>lipidomics</kwd><kwd>genetics</kwd><kwd>mediation effect</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>National Key R&amp;D Program of China</institution></institution-wrap></funding-source><award-id>2016YFC0900500</award-id><principal-award-recipient><name><surname>Guo</surname><given-names>Yu</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004440</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>202922/Z/16/Z</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Zhengming</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>81390540</award-id><principal-award-recipient><name><surname>Li</surname><given-names>Liming</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>81390544</award-id><principal-award-recipient><name><surname>Lv</surname><given-names>Jun</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Lifestyle interventions and statins may target different components of the lipid profile, suggesting that they are not redundant strategies but could be combined for better benefits.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Coronary heart disease (CHD) has become one of the leading causes of death worldwide (<xref ref-type="bibr" rid="bib31">Roth et al., 2018</xref>). In China, the mortality rate from CHD increased almost four times from 2002 to 2014 (<xref ref-type="bibr" rid="bib5">Chen et al., 2017</xref>). It is widely acknowledged that unhealthy lifestyles, such as smoking, excess alcohol consumption, inadequate physical activity, unhealthy diet, and adiposity, are major risk factors for CHD (<xref ref-type="bibr" rid="bib7">Dariush et al., 2008</xref>). Studies on the impacts of adherence to a combination of healthy lifestyle factors (HLFs) on mortality (<xref ref-type="bibr" rid="bib19">Li et al., 2018</xref>; <xref ref-type="bibr" rid="bib42">Zhu et al., 2019</xref>), healthy life expectancy (<xref ref-type="bibr" rid="bib20">Li et al., 2020</xref>), and risk of type 2 diabetes (<xref ref-type="bibr" rid="bib22">Lv et al., 2017a</xref>) and cardiovascular diseases in the Chinese population (<xref ref-type="bibr" rid="bib23">Lv et al., 2017b</xref>) have provided important information on the maximum public health benefit that lifestyle intervention could achieve.</p><p>Atherogenic dyslipidemia is one of the well-documented risk factors for CHD (<xref ref-type="bibr" rid="bib32">Shaima et al., 2016</xref>; <xref ref-type="bibr" rid="bib28">Peters et al., 2016</xref>). Conventional lipid markers fail to distinguish between the size, density, concentration, or composition of lipoprotein particles, which may have contrasting effects on CHD risk (<xref ref-type="bibr" rid="bib14">Holmes et al., 2018</xref>; <xref ref-type="bibr" rid="bib38">WÃ¼rtz et al., 2015</xref>). Lipidomics provides a detailed snapshot of the systemic lipid profile beyond routine lipid markers. Only a few studies have examined the association between lipidomic profile and individual HLFs separately (<xref ref-type="bibr" rid="bib17">Kujala et al., 2013</xref>; <xref ref-type="bibr" rid="bib39">WÃ¼rtz et al., 2016a</xref>; <xref ref-type="bibr" rid="bib37">WÃ¼rtz et al., 2014</xref>; <xref ref-type="bibr" rid="bib18">Lankinen et al., 2014</xref>), which, however, typically correlates with one another. It is mostly unknown how much of the effects of combined HLFs on reduced CHD risk are mediated through an improved lipid profile and what the differences are between components of the lipid profile in their mediating effects.</p><p>Statins are HMG-CoA reductase (HMGCR) inhibitors, which reduce the low-density lipoprotein cholesterol (LDL-C) by interfering with the cholesterol-biosynthetic pathway and have become one of the first-line therapy options for dyslipidemia (<xref ref-type="bibr" rid="bib33">Sirtori, 2014</xref>). Mendelian randomization studies constructed in the European population observed lipid-lowering effect of statins beyond the anticipated decrease in LDL particles (<xref ref-type="bibr" rid="bib10">Ference et al., 2019</xref>; <xref ref-type="bibr" rid="bib40">WÃ¼rtz et al., 2016b</xref>). However, such genetic effects have not been examined in Asian populations. No study compares the effects of healthy lifestyle and genetically inferred lipid-lowering medications on lipidomic profile in the same set of study participants.</p><p>The primary aims of the present study were to examine the combined effect of HLFs on components of a comprehensive lipidomic profile measured by nuclear magnetic resonance (NMR) spectroscopy (<xref ref-type="bibr" rid="bib34">Soininen et al., 2015</xref>), and further quantify how much of the combined effects of HLFs on CHD reduction are mediated through lipid metabolites. We also estimated the clinical effect of statins and bempedoic acid, a novel therapeutic approach by inhibiting ATP citrate lyase (ACLY) (<xref ref-type="bibr" rid="bib29">Pinkosky et al., 2016</xref>) on lipidomic profile by creating a Chinese specific genetic score for HMGCR and ACLY functions. Finally, we examined the joint effects of HLFs and lipid-lowering medications on lipidomic profile. We did a nested caseâcontrol study comprising incident CHD cases, stroke cases, and controls identified from the 10-year follow-up of the China Kadoorie Biobank (CKB). We included all eligible participants to examine the impact of HLFs and genetic scores on lipid metabolites, and only included CHD cases and controls in the further mediation analysis.</p></sec><sec id="s2" sec-type="results"><title>Results</title><p>The mean age of 4681 participants was 46.7Â Â±Â 8.0 years. Five HLFs included never smoking, moderate alcohol consumption, having a healthy dietary scoreÂ â¥4, being physically active, and healthy adiposity levels. Of theÂ 4681 participants, 0.2%, 11.1%, and 47.4% had at least 5, 4, and 3 HLFs, respectively. The overall mean (SD) LDL-C concentration measured by the clinical chemistry assay was 88.8 (27.0) mg/dl. Younger, female, and more educated participants were more likely to adopt a healthy lifestyle (<xref ref-type="table" rid="table1">Table 1</xref>). Compared with control participants, the CHD cases were older, were less likely to be women, and had a higher prevalence of hypertension and diabetes at baseline (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2A</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Age-, sex-, and study area-adjusted baseline characteristics of 4681 participants according to the number of healthy lifestyle factorsÂ (HLFs).</title><p>The results are presented as adjusted means or percentages, with adjustment for age, sex, and study area, as appropriate. All baseline characteristics were associated with the number of HLFs, with p&lt;0.05 for trend across categories, except for urban or rural residence (0.155), family history of heart attack (p<italic>=</italic>0.905), and consumption of fresh vegetables (0.065).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Baseline characteristics</th></tr><tr><th valign="top">0</th><th valign="top">1</th><th valign="top">2</th><th valign="top">3</th><th valign="top">â¥4</th></tr></thead><tbody><tr><td valign="top">No. of participants, n (%)</td><td>118 <break/>(2.5)</td><td>688 <break/>(14.7)</td><td>1656 <break/>(35.4)</td><td>1698 <break/>(36.3)</td><td>521 <break/>(11.1)</td></tr><tr><td valign="top">Age, year</td><td>49.6</td><td>49.0</td><td>47.5</td><td>45.8</td><td>43.8</td></tr><tr><td valign="top">Female, %</td><td>5.1</td><td>22.6</td><td>46.4</td><td>62.9</td><td>67.5</td></tr><tr><td valign="top">Urban area, %</td><td>42.6</td><td>33.5</td><td>27.8</td><td>25.1</td><td>36.6</td></tr><tr><td valign="top">Middle school and above, %</td><td>51.5</td><td>53.6</td><td>53.8</td><td>57.9</td><td>58.2</td></tr><tr><td valign="top">Married, %</td><td>91.3</td><td>92.9</td><td>94.6</td><td>95.3</td><td>95.2</td></tr><tr><td valign="top">Prevalent hypertension, %</td><td>62.6</td><td>52.6</td><td>48.7</td><td>40.6</td><td>38.5</td></tr><tr><td valign="top">Prevalent diabetes, %</td><td>13.8</td><td>12.0</td><td>7.1</td><td>4.1</td><td>3.8</td></tr><tr><td valign="top">Family history of heart attack, %</td><td>2.8</td><td>5.0</td><td>4.7</td><td>4.2</td><td>4.8</td></tr><tr><td valign="top">Having HLFs*, %</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td/></tr><tr><td valign="top">Never smoking</td><td>â</td><td>47.1</td><td>57.0</td><td>70.6</td><td>85.9</td></tr><tr><td valign="top">Moderate alcohol consumption</td><td>â</td><td>3.5</td><td>8.6</td><td>15.9</td><td>28.3</td></tr><tr><td valign="top">Being physically active</td><td>â</td><td>13.3</td><td>37.6</td><td>66.2</td><td>96.0</td></tr><tr><td valign="top">Healthy dietary pattern</td><td>â</td><td>23.9</td><td>41.4</td><td>60.2</td><td>94.0</td></tr><tr><td valign="top">Vegetables 7 days/week</td><td>90.8</td><td>93.2</td><td>92.5</td><td>93.0</td><td>97.6</td></tr><tr><td valign="top">Fruit 7 days/week</td><td>2.6</td><td>7.6</td><td>10.2</td><td>16.3</td><td>24.8</td></tr><tr><td valign="top">Read meatÂ &lt;7 days/week</td><td>52.9</td><td>65.7</td><td>73.7</td><td>76.7</td><td>84.8</td></tr><tr><td valign="top">Soybean productÂ â¥4 days/week</td><td>2.4</td><td>4.0</td><td>7.0</td><td>10.7</td><td>19.2</td></tr><tr><td valign="top">FishÂ â¥1 day/week</td><td>18.3</td><td>23.9</td><td>30.3</td><td>38.5</td><td>50.3</td></tr><tr><td valign="top">Coarse grainsÂ â¥4 days/week</td><td>7.9</td><td>21.1</td><td>22.7</td><td>23.7</td><td>25.0</td></tr><tr><td valign="top">Healthy adiposity level</td><td>â</td><td>25.8</td><td>55.5</td><td>89.0</td><td>98.0</td></tr></tbody></table><table-wrap-foot><fn><p>*HLFs were defined as: never smoking; weekly but not daily drinking or daily drinking less than 30 g of pure alcohol; engaging in a sex-specific median or higher level of physical activity; engaging in more than or equal to 4 of total six healthy diet components; having a body mass index between 18.5 and 27.9 kg/m<sup>2</sup> and having a waist circumferenceÂ &lt;90Â cm in men andÂ &lt;85 cm in women.</p></fn></table-wrap-foot></table-wrap><sec id="s2-1"><title>Associations of combined HLFs with lipid metabolites</title><p>Adherence to combined HLFs was associated with 50 components of the lipid profile (false dicovery rate [FDR] &lt; 0.05). Compared with participants who adopted at most one HLF, the differences in the lipid metabolites, especially VLDL- and HDL-related measures, increased with the number of HLFs adhered to (<xref ref-type="fig" rid="fig1">Figures 1</xref>â<xref ref-type="fig" rid="fig3">3</xref>). Participants with fourÂ toÂ five HLFs had lower VLDL particle concentrations and smaller VLDL particle size, with adjusted SD difference (95% CI) ranging from â0.54 (â0.66,â0.43) for large VLDL to â0.27 (â0.38,â0.15) for very small VLDL, and â0.47 (â0.59,â0.36) for VLDL diameter (<xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1âsource data 1</xref>). For HDL, adherence to fourÂ toÂ five HLFs was associated with higher HDL particle concentrations and larger HDL particle size, with maximum SD difference (95% CI) of 0.39 (0.28, 0.50) for large HDL, and 0.32 (0.21, 0.43) for HDL diameter. The corresponding SD difference (95% CI) for apolipoprotein B/apolipoprotein A1 was â0.45 (â0.56,â0.34), resulting from higher apolipoprotein A1 and lower apolipoprotein B.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Associations of size-specific lipoprotein particle concentrations, mean lipoprotein particle diameter, and apolipoprotein concentrations with combined healthy lifestyle and risk of coronary heart disease.</title><p>(<bold>a</bold>) SD difference and 95% CI are for comparison of participants who adopted twoÂ toÂ three or fourÂ toÂ five combined healthy lifestyles with participants who adopted zeroÂ toÂ one. Multivariable model was adjusted for: age, sex, fasting time, study areas, education level, and case/control status. (<bold>b</bold>) Odds ratio and 95% CI are for the associations of 1-SD metabolic markers increasing with CHD risk. Multivariable model was adjusted for: age, sex, fasting time, study areas, education level, and smoking status. Horizontal lines represent 95% CIs. ApoA1 = apolipoprotein A1; ApoB = apolipoprotein B; CHD = coronary heart disease; HDL = high-density lipoprotein; IDL = intermediate-density lipoprotein; LDL = low-density lipoprotein; Sig. = significance ***pâ¤0.0001, **pâ¤0.01, *pâ¤0.05,Â â p&gt;0.05 (false discovery rate [FDR]âadjusted p-values); VLDL =Â very low-density lipoprotein.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1âsource data 1.</label><caption><title>Associations of size-specific lipoprotein particle concentrations, mean lipoprotein particle diameter, and apolipoprotein concentrations with combined healthy lifestyle and risk of coronary heart disease.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-60999-fig1-data1-v1.docx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60999-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 1.</label><caption><title>Associations between number of healthy lifestyles and lipid metabolites.</title><p>Betas are linear regression coefficients per one increase in number of healthy lifestyles. Multivariable model was adjusted for: age, sex, fasting time, study areas, education level, and case/control status. Horizontal lines represent 95% CIs. Sig. = significance ***pâ¤0.0001, **pâ¤0.01, *pâ¤0.05,Â â p&gt;0.05 (false discovery rate [FDR]âadjusted p-values); Abbreviations as in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60999-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 2.</label><caption><title>Associations between number of healthy lifestyles and lipid metabolites without adjustment for fasting time.</title><p>Betas are linear regression coefficients per one increase in number of healthy lifestyles. Multivariable model was adjusted for: age, sex, study areas, education level, and case/control status. Horizontal lines represent 95% CIs. Sig. = significance ***pâ¤0.0001, **pâ¤0.01, *pâ¤0.05, â p&gt;0.05 (false discovery rate [FDR]âadjusted p-values); Abbreviations as in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60999-fig1-figsupp2-v1.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 3.</label><caption><title>Associations between number of healthy lifestyles and lipid metabolites with a more strict definition of healthy adiposity (bodyÂ massÂ index in the range of 18.5â24.9 kg/m<sup>2</sup> and waist circumferenceÂ &lt;90Â cm in men andÂ &lt;80 cm in women).</title><p>Betas are linear regression coefficients per one increase in number of healthy lifestyles. Multivariable model was adjusted for: age, sex, fasting time, study areas, education level, and case/control status. Horizontal lines represent 95% CIs. Sig. = significance ***pâ¤0.0001, **pâ¤0.01, *pâ¤0.05,Â â p&gt;0.05 (false discovery rate [FDR]âadjusted p-values); Abbreviations as in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60999-fig1-figsupp3-v1.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 4.</label><caption><title>Associations between number of healthy lifestyles and lipid metabolites without including moderate alcohol consumption as a healthy lifestyle.</title><p>Betas are linear regression coefficients per one increase in number of healthy lifestyles. Multivariable model was adjusted for: age, sex, fasting time, study areas, education level, and case/control status. Horizontal lines represent 95% CIs. Sig. = significance ***pâ¤0.0001, **pâ¤0.01, *pâ¤0.05,Â â p&gt;0.05 (false discovery rate [FDR]âadjusted p-values); Abbreviations as in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60999-fig1-figsupp4-v1.tif"/></fig><fig id="fig1s5" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 5.</label><caption><title>Associations between moderate alcohol consumption and lipid metabolites.</title><p>SD difference and 95% CI are for comparison of moderate alcohol drinker with others. Multivariable model was adjusted for: age, sex, fasting time, study areas, education level, case/control status,Â and other four lifestyle factors. Horizontal lines represent 95% CIs. Sig. = significance **pâ¤0.05, *pâ¤0.10,Â â p&gt;0.10 (false discovery rate [FDR]âadjusted p-values); Abbreviations as in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60999-fig1-figsupp5-v1.tif"/></fig><fig id="fig1s6" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 6.</label><caption><title>Associations between being physically active and lipid metabolites.</title><p>SD difference and 95% CI are for comparison of physically active participants with others. Multivariable model was adjusted for: age, sex, fasting time, study areas, education level, case/control status, andÂ other four lifestyle factors. Horizontal lines represent 95% CIs. Sig. = significance **pâ¤0.05, *pâ¤0.10,Â â p&gt;0.10 (false discovery rate [FDR]âadjusted p-values); Abbreviations as in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60999-fig1-figsupp6-v1.tif"/></fig><fig id="fig1s7" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 7.</label><caption><title>Associations between healthy adiposity level (bodyÂ massÂ index in the range of 18.5â27.9 kg/m<sup>2</sup> and waist circumferenceÂ &lt;90Â cm in men andÂ &lt;85 cm in women) and lipid metabolites.</title><p>SD difference and 95% CI are for comparison of participants with healthy adiposity with others. Multivariable model was adjusted for: age, sex, fasting time, study areas, education level, case/control status,Â and other four lifestyle factors. Horizontal lines represent 95% CIs. Sig. = significance **pâ¤0.05, *pâ¤0.10,Â â p&gt;0.10 (false discovery rate [FDR]âadjusted p-values); Abbreviations as in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60999-fig1-figsupp7-v1.tif"/></fig><fig id="fig1s8" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 8.</label><caption><title>Associations between healthy adiposity level (bodyÂ massÂ index in the range of 18.5â24.9 kg/m<sup>2</sup> and waist circumferenceÂ &lt;90Â cm in men andÂ &lt;80 cm in women) and lipid metabolites.</title><p>SD difference and 95% CI are for comparison of participants with healthy adiposity with others. Multivariable model was adjusted for: age, sex, fasting time, study areas, education level, case/control status, andÂ other four lifestyle factors. Horizontal lines represent 95% CIs. Sig. = significance **pâ¤0.05, *pâ¤0.10,Â â p&gt;0.10 (false discovery rate [FDR]âadjusted p-values); Abbreviations as in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60999-fig1-figsupp8-v1.tif"/></fig><fig id="fig1s9" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 9.</label><caption><title>Associations of alcohol consumption with size-specific lipoprotein particle concentrations, mean lipoprotein particle diameter, and apolipoprotein concentrations.</title><p>SD difference and 95% CI are for comparison of moderate alcohol drinker with others. Participants reporting weekly or daily drinking withÂ &lt;30 g of pure alcohol per day were defined as moderate alcohol use group; participants withÂ â¥30 g per day as heavy alcohol use. Multivariable model was adjusted for: age, sex, fasting time, study areas, education level, case/control status,Â and other four lifestyle factors. Horizontal lines represent 95% CIs. Sig. = significance ***pâ¤0.0001, **pâ¤0.01, *pâ¤0.05,Â â p&gt;0.05 (false discovery rate [FDR]âadjusted p-values); Abbreviations as in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60999-fig1-figsupp9-v1.tif"/></fig><fig id="fig1s10" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 10.</label><caption><title>Associations of alcohol consumption with cholesterol concentrations in lipoprotein subfractions.</title><p>SD difference and 95% CI are for comparison of moderate alcohol drinker with others. Participants reporting weekly or daily drinking withÂ &lt;30 g of pure alcohol per day were defined as moderate alcohol use group; participants withÂ â¥30 g per day as heavy alcohol use. Multivariable model was adjusted for: age, sex, fasting time, study areas, education level, case/control status, andÂ other four lifestyle factors. Horizontal lines represent 95% CIs. Sig. = significance ***pâ¤0.0001, **pâ¤0.01, *pâ¤0.05,Â â p&gt;0.05 (false discovery rate [FDR]âadjusted p-values); Abbreviations as in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60999-fig1-figsupp10-v1.tif"/></fig><fig id="fig1s11" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 11.</label><caption><title>Associations of alcohol consumption with triglyceride concentrations in lipoprotein subfractions.</title><p>SD difference and 95% CI are for comparison of moderate alcohol drinker with others. Participants reporting weekly or daily drinking withÂ &lt;30 g of pure alcohol per day were defined as moderate alcohol use group; participants withÂ â¥30 g per day as heavy alcohol use. Multivariable model was adjusted for: age, sex, fasting time, study areas, education level, case/control status, andÂ other four lifestyle factors. Horizontal lines represent 95% CIs. Sig. = significance ***pâ¤0.0001, **pâ¤0.01, *pâ¤0.05,Â â p&gt;0.05 (false discovery rate [FDR]âadjusted p-values); Abbreviations as in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60999-fig1-figsupp11-v1.tif"/></fig><fig id="fig1s12" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 12.</label><caption><title>Associations between never smoking and lipid metabolites.</title><p>SD difference and 95% CI are for comparison of never smokers with ever smokers. Multivariable model was adjusted for: age, sex, fasting time, study areas, education level, case/control status, andÂ other four lifestyle factors. Horizontal lines represent 95% CIs. Sig. = significance **pâ¤0.05, *pâ¤0.10,Â â p&gt;0.10 (false discovery rate [FDR]âadjusted p-values); Abbreviations as in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60999-fig1-figsupp12-v1.tif"/></fig><fig id="fig1s13" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 13.</label><caption><title>Associations between healthy diet pattern and lipid metabolites.</title><p>SD difference and 95% CI are for comparison of participants adopting a healthy diet pattern with others. Multivariable model was adjusted for: age, sex, fasting time, study areas, education level, case/control status, andÂ other four lifestyle factors. Horizontal lines represent 95% CIs. Sig. = significance **pâ¤0.05, *pâ¤0.10,Â â p&gt;0.10 (false discovery rate [FDR]âadjusted p-values); Abbreviations as in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60999-fig1-figsupp13-v1.tif"/></fig></fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Associations of cholesterol concentrations in lipoprotein subfractions with combined healthy lifestyle and risk of coronary heart disease.</title><p>(<bold>a</bold>) SD difference and 95% CI are for comparison of participants who adopted twoÂ toÂ three or fourÂ toÂ five combined healthy lifestyles with participants who adopted zeroÂ toÂ one. Multivariable model was adjusted for: age, sex, fasting time, study areas, education level, and case/control status. (<bold>b</bold>) Odds ratio and 95% CI are for the associations of 1-SD metabolic markers increasing with CHD risk. Multivariable model was adjusted for: age, sex, fasting time, study areas, education level, and smoking status. Horizontal lines represent 95% CIs. CHD = coronary heart disease; HDL2 = larger HDL particles; HDL3 = smaller HDL particles; Sig. = significance ***pâ¤0.0001, **pâ¤0.01, *pâ¤0.05,Â â p&gt;0.05 (false discovery rate [FDR]âadjusted p-values); other abbreviations as in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2âsource data 1.</label><caption><title>Associations of cholesterol concentrations in lipoprotein subfractions with combined healthy lifestyle and risk of coronary heart disease.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-60999-fig2-data1-v1.docx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60999-fig2-v1.tif"/></fig><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Associations of triglyceride concentrations in lipoprotein subfractions with combined healthy lifestyle and risk of coronary heart disease.</title><p>(<bold>a</bold>) SD difference and 95% CI are for comparison of participants who adopted two to three or four to five combined healthy lifestyles with participants who adopted zeroÂ toÂ one. Multivariable model was adjusted for: age, sex, fasting time, study areas, education level, and case/control status. (<bold>b</bold>) Odds ratio and 95% CI are for the associations of 1-SD metabolic markers increasing with CHD risk. Multivariable model was adjusted for: age, sex, fasting time, study areas, education level, and smoking status. Horizontal lines represent 95% CIs. CHD = coronary heart disease; Sig. = significance ***pâ¤0.0001, **pâ¤0.01, *pâ¤0.05,Â â p&gt;0.05 (false discovery rate [FDR]âadjusted p-values); Abbreviations as in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3âsource data 1.</label><caption><title>Associations of triglyceride concentrations in lipoprotein subfractions with combined healthy lifestyle and risk of coronary heart disease.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-60999-fig3-data1-v1.docx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60999-fig3-v1.tif"/></fig><p>The associations of combined HLFs with cholesterol concentrations in lipoprotein subfractions were very similar to the associations with the corresponding lipoprotein particle concentrations (<xref ref-type="fig" rid="fig2">Figure 2</xref>, <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2âsource data 1</xref>). Combined HLFs were consistently associated with lower TG concentrations in all lipoprotein subfractions except large HDL particles. The adjusted SD difference (95% CI) for participants with fourÂ toÂ five HLFs ranged from â0.55 (â0.66,â0.43) for small VLDL-TG to â0.29 (â0.41,â0.18) for medium LDL-TG (<xref ref-type="fig" rid="fig3">Figure 3</xref>, <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3âsource data 1</xref>).</p><p>The linear associations between each one factor increase in HLFs and lipid profile were illustrated in <xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1</xref>. In sensitivity analyses, we further adjusted for prevalent diabetes, restricted analyses to control participants (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2B</xref>), did not adjust for fasting time, used more strict body mass indexÂ (BMI) and waist circumference (WC) cut-off points to define healthy adiposity, or excluded moderate alcohol consumption from the HLF definition; the associations between HLFs and metabolites were not substantially altered (<xref ref-type="fig" rid="fig1s2">Figure 1âfigure supplements 2</xref>â<xref ref-type="fig" rid="fig1s4">4</xref>).</p></sec><sec id="s2-2"><title>Associations of individual HLFs with lipid metabolites</title><p>Of the five individual HLFs analyzed, moderate alcohol consumption (<xref ref-type="fig" rid="fig1s5">Figure 1âfigure supplement 5</xref>), being physically active (<xref ref-type="fig" rid="fig1s6">Figure 1âfigure supplement 6</xref>), and having healthy adiposity levels (<xref ref-type="fig" rid="fig1s7">Figure 1âfigure supplement 7</xref>), had the most significant influence on lipid metabolites. Participants who were physically active or had healthy adiposity levels had a cardioprotective lipid profile, with lower concentrations of VLDL-related measures, apolipoprotein B, and higher concentrations of larger HDL particles. The maximum SD differences (95% CI) related to physical activity (<xref ref-type="fig" rid="fig1s6">Figure 1âfigure supplement 6</xref>) and healthy adiposity level (<xref ref-type="fig" rid="fig1s7">Figure 1âfigure supplement 7</xref>) were â0.12 (â0.18,â0.06) for medium VLDL-TG and â0.54 (â0.60,â0.48) for total TG, respectively. Sensitivity analysis using more strict BMI and WC cut-off points (BMI in the range of 18.5â24.9 kg/m<sup>2</sup> and WCÂ &lt;90Â cm in men andÂ &lt;80 cm in women) observed similar and generally stronger associations between healthy adiposity level and lipidomic profile (<xref ref-type="fig" rid="fig1s8">Figure 1âfigure supplement 8</xref>).</p><p>Moderate alcohol consumption was associated with higher concentrations of VLDL-Â and HDL-related measures and apolipoprotein A1. The maximum SD difference (95% CI) was 0.29 (0.19, 0.38) for small HDL particle concentration (<xref ref-type="fig" rid="fig1s5">Figure 1âfigure supplement 5</xref>). We further divided participants into three groups according to their alcohol consumption at baseline: non-regular, moderate, and heavy use. Compared with non-regular use group, both heavy (withÂ â¥30 g of pure alcohol per day) and moderate alcohol use (&lt;30 g per day) had a similar pattern of effects on lipid metabolites, with the most significant changes observed in participants with heavy alcohol use (<xref ref-type="fig" rid="fig1s9">Figure 1âfigure supplements 9</xref>â<xref ref-type="fig" rid="fig1s11">11</xref>).</p><p>Smoking (<xref ref-type="fig" rid="fig1s12">Figure 1âfigure supplement 12</xref>) and dietary habit (<xref ref-type="fig" rid="fig1s13">Figure 1âfigure supplement 13</xref>) had a relatively small impact on lipid metabolites.</p></sec><sec id="s2-3"><title>Mediation effects of lipid metabolites in the association between HLFs and CHD risk</title><p>We restricted the following analyses in 927 incident CHD cases and 1513 controls. Incident CHD cases were those who developed fatal ischemic heart disease and nonfatal myocardial infarction during follow-up. The associations between lipid metabolites and CHD risk generally mirrored the associations between combined HLFs and lipid metabolites (<xref ref-type="fig" rid="fig1">Figures 1</xref>â<xref ref-type="fig" rid="fig3">3</xref>). None of the lipid metabolites showed interactions with the HLFs in their effect on CHD risk (all p<sub>interation</sub>Â &gt;Â 0.05). A total of 35 lipid metabolites showed statistically significant mediation effects from combined HLFs to CHD reduction (FDR ranging fromÂ &lt;0.001 to 0.042). The proportions of reduced CHD risk associated with combined HLFs mediated by VLDL particle concentration ranged from 4.77% for very small VLDL to 10.15% for small VLDL (<xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1âsource data 1</xref>). Other strong mediators included large HDL (8.02%), apolipoprotein B (8.36%), and apolipoprotein B/apolipoprotein A1 (11.32%). For cholesterol, compared to LDL-C, VLDL- and HDL-C were relatively strong mediators (<xref ref-type="fig" rid="fig2">Figure 2</xref>, <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2âsource data 1</xref>). TG carried within all lipoproteins (except for large-sized HDL) showed statistically significant mediating effects, with the maximum proportion of 10.47% for small VLDL-TG (<xref ref-type="fig" rid="fig3">Figure 3</xref>, <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3âsource data 1</xref>). The top five principal components of all lipid metabolites mediated 14.05% of the reduced CHD risk associated with combined HLFs.</p></sec><sec id="s2-4"><title><italic>HMGCR</italic> and <italic>ACLY</italic> scores, HLFs, and lipid metabolites</title><p>The <italic>HMGCR</italic> and <italic>ACLY</italic> scores had a similar pattern of effects on lipid metabolites, with higher scores mainly associated with decreased concentrations of intermediate-density lipoproteinÂ (IDL)-Â and LDL-related measures and apolipoprotein B (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2CÂ andÂ D</xref>). The sum of <italic>HMGCR</italic> and <italic>ACLY</italic> scores was associated with stronger changes in the above lipid metabolites (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2E</xref>). Use of genetic scores based on the European population (<xref ref-type="bibr" rid="bib10">Ference et al., 2019</xref>) for <italic>HMGCR</italic> and <italic>ACLY</italic> observed similar but weaker associations (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2CâF</xref>).</p><p>In the joint association analysis of HLFs and <italic>HMGCR</italic> score with lipid metabolites, compared with participants who had higher genetic risk (median cutoffs) and adhered to zeroÂ toÂ two HLFs, those with lower genetic risk and threeÂ toÂ five HLFs had the most cardioprotective lipidomic profile, including 0.36 SD decrease in VLDL-C, 0.13 SD decrease in LDL-C, and 0.21 SD increase in HDL-C (<xref ref-type="fig" rid="fig4">Figure 4</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1</xref> for <italic>ACLY</italic> score). We further compared the effect patterns of each one factor increase in HLFs with a 2-SD increase in <italic>HMGCR</italic> or <italic>ACLY</italic> score on lipid metabolites (<xref ref-type="fig" rid="fig4s2">Figure 4âfigure supplements 2</xref>Â andÂ <xref ref-type="fig" rid="fig4s3">3</xref>). The combined HLFs, as opposed to the effect by <italic>HMGCR</italic> and <italic>ACLY</italic> scores, were associated with lower VLDL-related measures, apolipoprotein B, and TG in almost all lipoprotein subfractions, and with higher HDL and HDL-C concentrations.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Joint association of combined healthy lifestyle and <italic>HMGCR</italic> scores based on Chinese population with lipid metabolites.</title><p>Participants who had higher genetic risk regarding HMGCR (3-hydroxy-3-methylglutarylâcoenzyme A reductase) and adhered to zeroÂ toÂ two healthy lifestyle factorsÂ (HLFs) were reference group. SD difference and 95% CI of log-transformed lipid metabolites for participants with lower genetic risk and 0-2 HLFs, higher genetic risk and 3-5 HLFs, and lower genetic risk and 3-5 HLFs were shown in red, blue, and green, respectively. Abbreviations as in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60999-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4âfigure supplement 1.</label><caption><title>Joint association of combined healthy lifestyle and <italic>ACLY</italic> score based on Chinese population with lipid metabolites.</title><p>Participants who had higher genetic risk regarding ACLY (ATP citrate lyase) and adhered to zeroÂ toÂ two healthy lifestyle factorsÂ (HLFs) were reference group. SD difference and 95% CI of log-transformed lipid metabolites for participants with lower genetic risk and 0â2 HLFs, higher genetic risk and 3â5 HLFs, and lower genetic risk and 3â5 HLFs were shown in red, blue, and green, respectively. Abbreviations as in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60999-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4âfigure supplement 2.</label><caption><title>Associations of combined healthy lifestyle and <italic>HMGCR</italic> score based on Chinese population with changes in the lipid metabolites.</title><p>SD difference and 95% CI of log-transformed lipid metabolites per one factor increase in healthy lifestyle factors were shown in blue. SD difference and 95% CI of log-transformed lipid metabolites per 2-SD higher HMGCR (3-hydroxy-3-methylglutarylâcoenzyme A reductase) score were shown in red. Abbreviations as in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60999-fig4-figsupp2-v1.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4âfigure supplement 3.</label><caption><title>Associations of combined healthy lifestyle and ACLY score based on Chinese population with changes in the lipid metabolites.</title><p>SD difference and 95% CI of log-transformed lipid metabolites per one factor increase in healthy lifestyle factors were shown in blue. SD difference and 95% CI of log-transformed lipid metabolites per 2-SD higher ACLY (ATP citrate lyase) score were shown in red. Abbreviations as inÂ <xref ref-type="fig" rid="fig1">Figure 1</xref> .</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60999-fig4-figsupp3-v1.tif"/></fig></fig-group><p>When we stratified participants according to the score of <italic>HMGCR</italic>, <italic>ACLY</italic>, or their sum score, the associations between each one factor increase in HLFs and lipid metabolites were generally similar between high- and low- genetic risk stratum (all p<sub>interaction</sub>Â &gt;0.05) (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2CâE</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In this prospective study of middle-aged Chinese, participants who adhered to healthy lifestyles tended to have a more cardioprotective lipidomic profile, which jointly mediated 14% of the protective effect of combined HLFs on CHD reduction. Similar to results in the European population, genetic scores for the targets of statins and ACLY inhibitors showed similar effects on reducing concentrations of IDL- and LDL-related measures, while the underlying mechanisms of lifestyle intervention were more strongly related to VLDL- and HDL-related measures, apolipoprotein B, and TG in almost all lipoprotein subfractions.</p><p>Our findings on the associations of lipid metabolites with individual lifestyle-related characteristics like physical activity, adiposity, and alcohol consumption were generally consistent with previous studies (<xref ref-type="bibr" rid="bib17">Kujala et al., 2013</xref>; <xref ref-type="bibr" rid="bib39">WÃ¼rtz et al., 2016a</xref>; <xref ref-type="bibr" rid="bib37">WÃ¼rtz et al., 2014</xref>). One of the studies used the Mendelian randomization to indicate causal adverse effects of increased adiposity on lipoprotein subclass profiles within the non-obese weight range among young Finland adults (<xref ref-type="bibr" rid="bib37">WÃ¼rtz et al., 2014</xref>). Another study similarly showed a mixture of favorable and adverse effects of alcohol consumption on the lipid profile in relation to cardiovascular disease (<xref ref-type="bibr" rid="bib39">WÃ¼rtz et al., 2016a</xref>). Also, the lipoprotein lipid profile observed cross-sectionally was highly consistent with the pattern of their changes accompanying a change in alcohol consumption at 6-year follow-up. Numerous studies have found increased HDL level with higher alcohol consumption (<xref ref-type="bibr" rid="bib11">Gepner et al., 2015</xref>; <xref ref-type="bibr" rid="bib2">Brien et al., 2011</xref>). However, the association between alcohol consumption and apolipoprotein B-carrying lipoprotein is less clear (<xref ref-type="bibr" rid="bib2">Brien et al., 2011</xref>; <xref ref-type="bibr" rid="bib30">Roerecke and Rehm, 2014</xref>). Our results noted that alcohol consumption showed divergent relationships with different sized apolipoprotein B-carrying particles, forÂ example, higher concentration of large-sized VLDL and lower concentration of IDL and LDL. Although the explanation for the complex association between alcohol consumption and lipid profile remains inconclusive, our detailed investigation of lipoprotein subclasses provides improved understanding of the diverse molecular process related to alcohol consumption. Regarding diet, a previous randomized trial found that diet in rich of whole grain, bilberries, and fatty fish caused changes in HDL particles (<xref ref-type="bibr" rid="bib18">Lankinen et al., 2014</xref>). The present study characterized a healthy diet differently and found significant differences in VLDL-related measures but not HDL.</p><p>This is the first study, to our knowledge, to assess the combined effect of HLFs on a comprehensive lipidomic profile. The results indicatedÂ that participants with healthy lifestyles were characterized by an antiatherogenic lipidomic profile, which has been related to lower CHD risk previously (<xref ref-type="bibr" rid="bib36">Varbo et al., 2013</xref>; <xref ref-type="bibr" rid="bib13">Holmes et al., 2015</xref>; <xref ref-type="bibr" rid="bib27">Peter et al., 2015</xref>; <xref ref-type="bibr" rid="bib26">Natarajan et al., 2010</xref>; <xref ref-type="bibr" rid="bib15">Inouye et al., 2010</xref>). The positive associations of combined HLFs with HDL and HDL-C were limited to large and medium subclasses, in line with previous studies which suggested that small HDL particles didÂ not have protective effects on CHD (<xref ref-type="bibr" rid="bib27">Peter et al., 2015</xref>; <xref ref-type="bibr" rid="bib26">Natarajan et al., 2010</xref>; <xref ref-type="bibr" rid="bib15">Inouye et al., 2010</xref>). Notably, the TG levels within all apolipoprotein B and most HDL particles were lower in participants who adopted healthy lifestyles. It is plausible that healthy lifestyles have opposing relationships with HDL-TG and HDL-C.</p><p>Limited prospective studies have investigated the mediating effects of individual HLFs on CHD through total cholesterol, suggestingÂ that it mediates 13%, 8%, and 18% of the excess CHD risk related to inadequate physical activity (<xref ref-type="bibr" rid="bib25">Mora et al., 2007</xref>), obesity, and overweight (<xref ref-type="bibr" rid="bib12">Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration (BMI Mediated Effects), 2014</xref>), respectively. Our results showed all NMR-measured lipid metabolites jointly explained 14% of the protective effect of combined HLFs on CHD risk. We further highlighted the differences between various lipid metabolites in their mediating effects. The apolipoprotein B/A1 ratio was among the most influential mediators and has been previously reported to be a better predictor of CHD risk than any of the cholesterol ratios (<xref ref-type="bibr" rid="bib24">McQueen et al., 2008</xref>). A lower apolipoprotein B/A1 ratio, together with manifestation of other metabolites, suggested thatÂ adherence to HLFs can reduce the risk of CHD through both lower proatherogenic and higher antiatherogenic lipoproteins.</p><p>Both statins and ACLY inhibitors have been associated with lowering LDL- and IDL-related measures and further with a reduction in CVD risk in western populations (<xref ref-type="bibr" rid="bib10">Ference et al., 2019</xref>; <xref ref-type="bibr" rid="bib40">WÃ¼rtz et al., 2016b</xref>). In the present study, we used genetic scores to mimic the effects of these two LDL-C lowering targets and observed similar effects on the lipidomic profile. For LDL and IDL particle concentrations, adherence to two or more HLFs could achieve a similar beneficial effect as a 2-SD change in <italic>ACLY</italic>/<italic>HMGCR</italic> genetic scores. In other words, two or more HLFs could compensate for the deleterious effect on lipid metabolites due to inheriting risk alleles in these genes. More importantly, we found that adherence to combined HLFs had a much stronger effect on other components of the lipidomic profile than LDL- and IDL-related measures, including VLDL- and HDL-related components.</p><p>To our knowledge, this is the first study to reveal the potential underlying lipid pathways that may mediate the effects of adherence to combined HLFs on lower CHD risk. The strengths of the study include the prospective outcome ascertainment, a comprehensive assessment of lifestyle factors, and a population free of lipid-modifying therapy at the time of blood collection. The measurements of multiple lipids and lipoprotein particles provide a detailed snapshot of the systemic lipid profile. The concordance of measurements by both NMR spectroscopy and clinical chemistry assays, and by duplicate samples of NMR metabolomics provided evidence to support internal validity. The availability of genotyping data allowed us to use a Mendelian randomization approach to estimate the effects of statins and ACLY inhibition on lipid metabolites while avoiding potential confounding bias by indication.</p><p>Our study has limitations. First, the lifestyle behaviors were self-reported once at baseline. Second, lifestyle behaviors and lipid metabolites were measured at the same time. However, previous evidence supports the causative effects of individual HLFs on lipid metabolites and the resemblance between the cross-sectional and longitudinal association patterns (<xref ref-type="bibr" rid="bib39">WÃ¼rtz et al., 2016a</xref>; <xref ref-type="bibr" rid="bib37">WÃ¼rtz et al., 2014</xref>). Third, the lipid metabolites quantified by the NMR spectroscopy assay did not include some important measures such as lipoprotein(a), apolipoprotein CIII, and HDL functionality. There are also strong correlations between the lipid metabolites, with multiple measures representing the same underlying lipid fractions. As a result, the mediating role of lipid metabolites in the present study cannot extrapolate to that of the complete lipidomic profile and also cannot differentiate the individual mediating role of each lipid metabolites. Nevertheless, this does not detract from the value of the study in identifying potential pathways underlying the HLFs and CHD risk. Fourth, the effect of therapeutic agents mimicked by genetic scores is the effect of lifelong exposure to a biomarker on an outcome that is difficult to be translated into the expected effect of short-term pharmacologic changes (<xref ref-type="bibr" rid="bib10">Ference et al., 2019</xref>). However, genetic scores served mainly for comparison of the underlying mechanisms of lifestyle interventions and lipid-lowering medications, rather than the effect size. Lastly, a more sophisticated HLFs score with appropriated weight might show stronger association. However, a more straightforward definition would be easier to understand and adapted by the public. Also, mediation analysis might be biased when the continuous exposure variable was dichotomized. Our simulation showed that this requires a particularly strong association between exposure and mediator, which was far from the realistic association between HLFs and metabolite in our study.</p><p>The present study of Chinese adults elucidated that the effects of adherence to a combination of HLFs on lower CHD risk were partly mediated by an improved lipid profile. Lifestyle interventions and lipid-lowering medication therapies may affect different components of the lipid profile, suggesting that they are not redundant strategies but could be combined for better benefits.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Study population</title><p>The CKB is a prospective cohort of 512,715 adults (aged 30â79 years) from 10 geographically diverse areas across China (five urban sites and five rural sites) during 2004â2008. Details of the study design, survey methods, and long-term follow-up have been given elsewhere (<xref ref-type="bibr" rid="bib3">Chen et al., 2005</xref>; <xref ref-type="bibr" rid="bib4">Chen et al., 2011</xref>). Briefly, all participants had baseline data collected by questionnaire, including sociodemographic, lifestyle factors, and medical and medication history, and physical measurements. Participants also provided a 10 ml random blood sample for long-term storage, with the time since last meal recorded. Mortality and morbidity during follow-up were identified through linkage with local death and disease registries, with the national health insurance system, and by active follow-up if necessary (i.e., visiting local communities or directly contacting participants). Since 2014, 97% of the participants have been linked to the health insurance databases. By December 31, 2015, of all theÂ cohort participants, only 4875 (&lt;1%) were lost to follow-up. The mean follow-up duration of the cohort since baseline was 9.2 (1.4) years.</p><p>The study protocol was approved by the Ethics Review Committee of the Chinese Center for Disease Control and Prevention (005/2004, Beijing, China) and the Oxford Tropical Research Ethics Committee, University of Oxford (025â04, UK). All participants provided written informed consent.</p></sec><sec id="s4-2"><title>Design of the present study</title><p>A subset of 4681 CKB participants was selected for metabolomics measurements in a nested caseâcontrol study of incident CHD and stroke occurring before the censoring date of January 1, 2015 (<xref ref-type="bibr" rid="bib14">Holmes et al., 2018</xref>). Cases were those who had a newly developed fatal or nonfatal disease during follow-up: (1) CHD: fatal ischemic heart disease coded as ICD-10 I20-I25 and nonfatal myocardial infarction coded as I21-I23 (nÂ =Â 927); (2) ischemic stroke: ICD-10 I63 or I69.3 (nÂ =Â 1114); (3) intracerebral hemorrhage: ICD-10 I61 or I69.1 (nÂ =Â 1127). Case status was defined as the disease first occurred in each participant. Common controls were selected by frequency matching to combined cases by age, sex, and study area (nÂ =Â 1513). The diagnosis adjudication has finished for 34,000 reported cases of ischemic heart disease by a review of hospital medical records. Overall, 88% of the diagnoses were confirmed. All case and control participants did not report doctor-diagnosed CHD, stroke, transient ischemic attack, or cancer, and were not using statins and other lipid-lowering medications at baseline. Of the 4681 participants, 4592 had genotyping information, which was generated using a customized Affymetrix Axiom array includingÂ ~800,000 SNPs and further imputed to the 1000 Genomes reference panel (Phase 3) using IMPUTE v2.</p></sec><sec id="s4-3"><title>Measurement of lipid metabolites</title><p>A high-throughput targeted NMR metabolomics platform (<xref ref-type="bibr" rid="bib34">Soininen et al., 2015</xref>) was used for quantification of circulating lipid metabolites in baseline plasma samples (Brainshake Laboratory at Kuopio, Finland). All metabolites were assayed simultaneously. Cases and controls were measured in random order, with laboratory staff blinded to case/control status. Of theÂ 4681 participants, 137 had duplicated measurements. The median coefficient of variation for duplicates was 5.0% (interquartile range: 2.7â6.7%) (<xref ref-type="bibr" rid="bib14">Holmes et al., 2018</xref>). Six traits covered by NMR spectroscopy were also measured using standard clinical chemistry assays including total cholesterol, LDL-C, high-density lipoprotein cholesterol (HDL-C), triglyceride (TG), apolipoprotein B, and apolipoprotein A1 (Wolfson Laboratory at University of Oxford, UK). There were high correlations between NMR and clinical chemistry measured traits, with the correlation ranging from 0.80 to 0.90 (<xref ref-type="bibr" rid="bib14">Holmes et al., 2018</xref>).</p></sec><sec id="s4-4"><title>Definition and assessment of HLFs</title><p>We included five baseline lifestyle-related characteristics: smoking, alcohol consumption, dietary habit, physical activity, and body weight and fat to assess energy balance (<xref ref-type="bibr" rid="bib21">Lloyd-Jones et al., 2010</xref>). In the baseline questionnaire, for smoking, we asked frequency, type, and amount of tobacco smoked per day for ever smokers, and years since quitting and reason to quit for former smokers. For alcohol consumption, we asked drinking frequency on a week, type of alcoholic beverage, and volume of alcohol consumed on a typical drinking day. For physical activity, we asked the usual type and duration of activities. The daily level of physical activity was calculated by multiplying the metabolic equivalent tasks (METs) value for a particular type of physical activity by hours spent on that activity per day and summing the METÂ hours for all activities. For dietary habit, we used a short qualitative food frequency questionnaire to assess habitual intakes of 12 conventional food groups (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2G</xref>). For adiposity level, trained staff measured weight, height, and WC with calibrated instruments. BMI was calculated as weight in kilograms divided by the square of the height in meters.</p><p>The HLFs that may be related to lower CHD risk were defined as follows: (1) never smoking; (2) moderate alcohol consumption: weekly but not daily drinking, or daily drinking less than 30 g of pure alcohol; (3) havingÂ â¥4 of the total six healthy dietary habits that are particularly addressed in the Chinese dietary guidelines (2016) (<xref ref-type="bibr" rid="bib41">Yang et al., 2018</xref>): consuming fresh vegetables every day, fresh fruits every day, red meatÂ &lt;7 days/week, soybean productsÂ â¥4 days/week, fishÂ â¥1 day/week, and coarse grainsÂ â¥4 days/week; (4) being physically active, i.e. having a sex-specific median or higher level of physical activity; (5) healthy adiposity levels: BMI in the range of 18.5â27.9 kg/m<sup>2</sup> (normal or overweight according to the standard classification specific for Chinese) and WCÂ &lt;90Â cm in men andÂ &lt;85 cm in women (<xref ref-type="bibr" rid="bib6">Chen et al., 2018</xref>; <xref ref-type="bibr" rid="bib16">Jia et al., 2010</xref>).</p></sec><sec id="s4-5"><title>Genetic scores for <italic>HMGCR</italic> and <italic>ACLY</italic></title><p>We constructed the genetic scores in the Chinese population with a previously adopted method (<xref ref-type="bibr" rid="bib10">Ference et al., 2019</xref>). This approach has been used to accurately anticipate the results of several randomized trials that have evaluated lipid-lowering therapies (<xref ref-type="bibr" rid="bib9">Ference, 2018</xref>). First, we tested the association of each variant within a 500 KB window on either side of the <italic>HMGCR</italic> gene in a linear regression model, with plasma LDL-C as dependent variable and age, sex, and the top 10 ancestry-informative principal components as covariates in 13,060 participants from the CKB cohort without overlapping with the lipidomic dataÂ set. All 13,060 participants were not using statin and other lipid-lowering medications at baseline. Second, we pruned the variant by keeping the top variants with most significant p-value and removed other variants that were correlated with the selected variant (r<sup>2</sup>Â &gt;Â 0.3). Next, we tested the association between each remaining variant and LDL-C, conditional on previously selected variants and covariates, and selected the variant with the smallest p-value. We iteratively repeated this step until all variants were selected, removed due to linkage disequilibrium with a selected variant, or were not associated with LDL-C (p&gt;0.05). The exposure allele for each selected variant was defined as the allele associated with lower plasma LDL-C. The weight for each variant was the conditional effect of that variant on LDL-C level in mmol/l adjusted for all other variants included in the score among the 13,060 participants.</p><p>We multiplied the number of exposure alleles that a participant inherited at each variant by their weights. We then summed these values to construct a weighted <italic>HMGCR</italic> genetic score for each participant in the present analysis. We used the same protocol to construct a weighted <italic>ACLY</italic> genetic score. We called this as genetic score based on Chinese population.</p><p>We also used previously constructed <italic>HMGCR</italic> and <italic>ACLY</italic> genetic scores (<xref ref-type="bibr" rid="bib10">Ference et al., 2019</xref>) for comparison with studies in the European population. Three of the total nine variants included in the <italic>ACLY</italic> genetic score (rs113201466, rs145940140, and rs117981684) were monomorphism in the eastern Asian population. Only the other six variants were used to construct the genetic score for <italic>ACLY</italic>. Linear regression was used to estimate the effect of each variant on LDL-C level, with adjustment for age, sex, and the top 10 ancestry-informative principal components. We called this as genetic score based on European population. We also used the conditional effect reported from the previous study (<xref ref-type="bibr" rid="bib10">Ference et al., 2019</xref>) to construct alternative weighted genetic scores for sensitivity analyses.</p><p>Variants included in the genetic scores and their association with LDL-C were provided in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2H</xref>.</p></sec><sec id="s4-6"><title>Statistical analysis</title><p>We classified participants into three groups according to the number of HLFs they adopted: zeroÂ toÂ one, twoÂ toÂ three, and fourÂ toÂ five. All lipid metabolites were inverse normal transformed (SDÂ =Â 1), which is useful for comparing variables expressed in different units. The associations between combined HLFs and lipid metabolites were assessed using linear regression adjusted for age (years), sex (male or female), fasting time (&lt;8 orÂ â¥8 hr), 10Â study areas, education level (no formal or primary school, middle or high school, technical school or college or higher), and case/control status, with participants who adopted zeroÂ toÂ one HLF as the reference group. Logistic regression was used to estimate odds ratios (ORs) of CHD per 1-SD higher lipid metabolite levels, adjusted for age, sex, fasting time, study areas, education level, and smoking status. The additional adjustment was also made for other HLFs (alcohol consumption, dietary habit, physical activity, and BMI) and prevalent diabetes, with results largely unchanged (data not shown).</p><p>We used the paramed package (<xref ref-type="bibr" rid="bib8">Emsley and Liu, 2013</xref>) to perform causal mediation analysis (<xref ref-type="bibr" rid="bib35">Valeri and VanderWeele, 2013</xref>) using parametric regression models. For each lipid metabolite, two models were estimated: (1) a model for the mediator (the lipid metabolite itself) conditional on exposure (the number of HLFs as a continuous variable) and covariates (age, sex, fasting time, study areas, and education level) in the control participants only (nÂ =Â 1513); (2) a model for the risk of CHD conditional on exposure, the mediator, and covariates (age, sex, fasting time, study areas, and education level) in both CHDÂ case and control participants (nÂ =Â 2440). We also allowed for the presence of exposure-mediator interactions in the outcome regression model. We aimed to access how much of the total effect (TE) is due to neither mediation nor interaction; how much is due to interaction but not mediation; how much is due to both mediation and interaction; and how much of the effect is due to mediation but not interaction (natural indirect effect [NIE]). We used the delta method to estimate standard errors and confidence intervals. If exposure-mediator interactions did not exist, the proportion attributable to the NIE was calculated by dividing the NIE by TE on log odds scale, with 0 indicating no mediation effect. We also used the top five principal components of all lipid metabolites that explainedÂ â¥95% of the total variation to estimate the joint mediating effect of all lipid metabolites.</p><p>The <italic>HMGCR</italic> and <italic>ACLY</italic> genetic scores were also inverse normal transformed to facilitate comparisons. We estimated the association of a 2-SD increase in the <italic>HMGCR</italic> or <italic>ACLY</italic> score with lipid metabolites using linear regression, with adjustment for age, sex, study areas, and the top 10 genotype principal components. We further examined the joint association of HLFs and genetic scores with lipid metabolites, by classifying participants into four groups according to their genetic score (median cutoffs) and number of HLFs (zeoÂ toÂ two or threeÂ toÂ five). We also examined whether the association between HLFs and lipid metabolites differed by scores of <italic>HMGCR</italic>, <italic>ACLY</italic>, or their sum score, which were dichotomized according to the median cutoffs of the genetic scores. The tests for interaction were performed using likelihood ratio tests comparing models with and without the cross-product term.</p><p>All analyses were performed with Stata version 14.2 (StataCorp) and R software version 3.5.2 (R Foundation for Statistical Computing). p-values are presented as unadjusted for multiple testing unless otherwise indicated. For testing of multiple lipid metabolites, we used the FDR (<xref ref-type="bibr" rid="bib1">Benjamini and Hochberg, 1995</xref>) &lt;0.05.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>The most important acknowledgement is to the participants in the study and the members of the survey teams in each of the 10 regional centers, as well as to the project development and management teams based at Beijing, Oxford and the 10 regional centers.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Formal analysis, Visualization, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Validation, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Data curation, Funding acquisition, Investigation, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Data curation, Investigation, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Data curation, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Data curation, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Data curation, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Data curation, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con10"><p>Data curation, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con11"><p>Data curation, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con12"><p>Data curation, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con13"><p>Data curation, Investigation, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con14"><p>Data curation, Supervision, Investigation, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Resources, Data curation, Supervision, Funding acquisition, Investigation, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con16"><p>Conceptualization, Supervision, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con17"><p>Conceptualization, Data curation, Supervision, Funding acquisition, Investigation, Methodology, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: The study protocol was approved by the Ethics Review Committee of the Chinese Center for Disease Control and Prevention (005/2004, Beijing, China) and the Oxford Tropical Research Ethics Committee, University of Oxford (025-04, UK). All participants provided written informed consent.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="scode1"><label>Source code 1.</label><caption><title>Association between lifestyle and metabolites.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-60999-code1-v1.zip"/></supplementary-material><supplementary-material id="scode2"><label>Source code 2.</label><caption><title>Association between metabolites and CHD.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-60999-code2-v1.zip"/></supplementary-material><supplementary-material id="scode3"><label>Source code 3.</label><caption><title>Joint effect of genetic score and HLFs on CHD.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-60999-code3-v1.zip"/></supplementary-material><supplementary-material id="scode4"><label>Source code 4.</label><caption><title>Mediation analysis.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-60999-code4-v1.zip"/></supplementary-material><supplementary-material id="scode5"><label>Source code 5.</label><caption><title>Construction of genetic scores.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-60999-code5-v1.zip"/></supplementary-material><supplementary-material id="scode6"><label>Source code 6.</label><caption><title>Simulation of mediation analysis.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-60999-code6-v1.zip"/></supplementary-material><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Members of the China Kadoorie Biobank collaborative group.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-60999-supp1-v1.docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Baseline characteristics according to case or control status, results of sensitivity analysis, and other useful materials in the methods section.</title><p>(A) Age-, sex-, and study area-adjusted baseline characteristics of 4681 participants according to case or control status.Â (B) Sensitivity analysis of association between combined healthy lifestyle and lipid metabolites. (C) Associations of the <italic>HMGCR</italic> score with changes in the lipid metabolites, and subgroup analysis of the association between healthy lifestyle and lipid metabolites according to <italic>HMGCR</italic> score. (D) Associations of the <italic>ACLY</italic> score with changes in the lipid metabolites, and subgroup analysis of the association between healthy lifestyle and lipid metabolites according to <italic>ACLY</italic> score. (E) Associations of the sum of <italic>HMGCR</italic> and <italic>ACLY</italic> score with changes in the lipid metabolites, and subgroup analysis of the association between healthy lifestyle and lipid metabolites according to the sum score. (F) Associations of the genetic scores* with changes in the lipid metabolites. (G) Food frequency questionnaire used in the CKB study at baseline. (H) Variants included in the genetic scores and their associations with plasma low-density lipoprotein cholesterol.</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-60999-supp2-v1.docx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-60999-transrepform-v1.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>According to the Regulation of the People's Republic of China on the Administration of Human Genetic Resources, we are not allowed to provide Chinese human clinical and genetic data abroad without an official approval. We are providing our syntax of statistical analysis and the output from the analysis.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamini</surname> <given-names>Y</given-names></name><name><surname>Hochberg</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Controlling the false discovery rate: a practical and powerful approach to multiple testing</article-title><source>Journal of the Royal Statistical Society: Series B</source><volume>57</volume><fpage>289</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1111/j.2517-6161.1995.tb02031.x</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brien</surname> <given-names>SE</given-names></name><name><surname>Ronksley</surname> <given-names>PE</given-names></name><name><surname>Turner</surname> <given-names>BJ</given-names></name><name><surname>Mukamal</surname> <given-names>KJ</given-names></name><name><surname>Ghali</surname> <given-names>WA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: systematic review and meta-analysis of interventional studies</article-title><source>BMJ</source><volume>342</volume><elocation-id>d636</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.d636</pub-id><pub-id pub-id-type="pmid">21343206</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>Z</given-names></name><name><surname>Lee</surname> <given-names>L</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Collins</surname> <given-names>R</given-names></name><name><surname>Wu</surname> <given-names>F</given-names></name><name><surname>Guo</surname> <given-names>Y</given-names></name><name><surname>Linksted</surname> <given-names>P</given-names></name><name><surname>Peto</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Cohort profile: the kadoorie study of chronic disease in China (KSCDC)</article-title><source>International Journal of Epidemiology</source><volume>34</volume><fpage>1243</fpage><lpage>1249</lpage><pub-id pub-id-type="doi">10.1093/ije/dyi174</pub-id><pub-id pub-id-type="pmid">16131516</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>Z</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Collins</surname> <given-names>R</given-names></name><name><surname>Guo</surname> <given-names>Y</given-names></name><name><surname>Peto</surname> <given-names>R</given-names></name><name><surname>Wu</surname> <given-names>F</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><collab>China Kadoorie Biobank (CKB) collaborative group</collab></person-group><year iso-8601-date="2011">2011</year><article-title>China kadoorie biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up</article-title><source>International Journal of Epidemiology</source><volume>40</volume><fpage>1652</fpage><lpage>1666</lpage><pub-id pub-id-type="doi">10.1093/ije/dyr120</pub-id><pub-id pub-id-type="pmid">22158673</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>W-W</given-names></name><name><surname>R-l</surname> <given-names>GAO</given-names></name><name><surname>L-s</surname> <given-names>LIU</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>China cardiovascular diseases report 2015: a summary</article-title><source>J Geriatr Cardiol JGC</source><volume>11</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.11909/j.issn.1671-5411.2017.01.012</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>C</given-names></name><name><surname>Shang</surname> <given-names>H</given-names></name><name><surname>Yang</surname> <given-names>K</given-names></name><name><surname>Norris</surname> <given-names>SL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Clinical practice guidelines in China</article-title><source>BMJ</source><volume>360</volume><elocation-id>j5158</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.j5158</pub-id><pub-id pub-id-type="pmid">29437564</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dariush</surname> <given-names>M</given-names></name><name><surname>Wilson Peter</surname> <given-names>WF</given-names></name><name><surname>Kannel William</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Beyond established and novel risk factors</article-title><source>Circulation</source><volume>117</volume><fpage>3031</fpage><lpage>3038</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.738732</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Emsley</surname> <given-names>R</given-names></name><name><surname>Liu</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>PARAMED: stata module to perform causal mediation analysis using parametric regression models</article-title><ext-link ext-link-type="uri" xlink:href="https://econpapers.repec.org/software/bocbocode/s457581.htm">https://econpapers.repec.org/software/bocbocode/s457581.htm</ext-link><date-in-citation iso-8601-date="2019-05-16">May 16, 2019</date-in-citation></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ference</surname> <given-names>BA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>How to use mendelian randomization to anticipate the results of randomized trials</article-title><source>European Heart Journal</source><volume>39</volume><fpage>360</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehx462</pub-id><pub-id pub-id-type="pmid">29020392</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ference</surname> <given-names>BA</given-names></name><name><surname>Ray</surname> <given-names>KK</given-names></name><name><surname>Catapano</surname> <given-names>AL</given-names></name><name><surname>Ference</surname> <given-names>TB</given-names></name><name><surname>Burgess</surname> <given-names>S</given-names></name><name><surname>Neff</surname> <given-names>DR</given-names></name><name><surname>Oliver-Williams</surname> <given-names>C</given-names></name><name><surname>Wood</surname> <given-names>AM</given-names></name><name><surname>Butterworth</surname> <given-names>AS</given-names></name><name><surname>Di Angelantonio</surname> <given-names>E</given-names></name><name><surname>Danesh</surname> <given-names>J</given-names></name><name><surname>Kastelein</surname> <given-names>JJP</given-names></name><name><surname>Nicholls</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mendelian randomization study of <italic>ACLY</italic> and cardiovascular disease</article-title><source>New England Journal of Medicine</source><volume>380</volume><fpage>1033</fpage><lpage>1042</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1806747</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gepner</surname> <given-names>Y</given-names></name><name><surname>Golan</surname> <given-names>R</given-names></name><name><surname>Harman-Boehm</surname> <given-names>I</given-names></name><name><surname>Henkin</surname> <given-names>Y</given-names></name><name><surname>Schwarzfuchs</surname> <given-names>D</given-names></name><name><surname>Shelef</surname> <given-names>I</given-names></name><name><surname>Durst</surname> <given-names>R</given-names></name><name><surname>Kovsan</surname> <given-names>J</given-names></name><name><surname>Bolotin</surname> <given-names>A</given-names></name><name><surname>Leitersdorf</surname> <given-names>E</given-names></name><name><surname>Shpitzen</surname> <given-names>S</given-names></name><name><surname>Balag</surname> <given-names>S</given-names></name><name><surname>Shemesh</surname> <given-names>E</given-names></name><name><surname>Witkow</surname> <given-names>S</given-names></name><name><surname>Tangi-Rosental</surname> <given-names>O</given-names></name><name><surname>Chassidim</surname> <given-names>Y</given-names></name><name><surname>Liberty</surname> <given-names>IF</given-names></name><name><surname>Sarusi</surname> <given-names>B</given-names></name><name><surname>Ben-Avraham</surname> <given-names>S</given-names></name><name><surname>Helander</surname> <given-names>A</given-names></name><name><surname>Ceglarek</surname> <given-names>U</given-names></name><name><surname>Stumvoll</surname> <given-names>M</given-names></name><name><surname>BlÃ¼her</surname> <given-names>M</given-names></name><name><surname>Thiery</surname> <given-names>J</given-names></name><name><surname>Rudich</surname> <given-names>A</given-names></name><name><surname>Stampfer</surname> <given-names>MJ</given-names></name><name><surname>Shai</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Effects of initiating moderate alcohol intake on cardiometabolic risk in adults with type 2 diabetes: a 2-Year randomized, controlled trial</article-title><source>Annals of Internal Medicine</source><volume>163</volume><fpage>569</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.7326/M14-1650</pub-id><pub-id pub-id-type="pmid">26458258</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration (BMI Mediated Effects)</collab></person-group><year iso-8601-date="2014">2014</year><article-title>Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1Â·8 million participants</article-title><source>The Lancet</source><volume>383</volume><fpage>970</fpage><lpage>983</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(13)61836-X</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holmes</surname> <given-names>MV</given-names></name><name><surname>Asselbergs</surname> <given-names>FW</given-names></name><name><surname>Palmer</surname> <given-names>TM</given-names></name><name><surname>Drenos</surname> <given-names>F</given-names></name><name><surname>Lanktree</surname> <given-names>MB</given-names></name><name><surname>Nelson</surname> <given-names>CP</given-names></name><name><surname>Dale</surname> <given-names>CE</given-names></name><name><surname>Padmanabhan</surname> <given-names>S</given-names></name><name><surname>Finan</surname> <given-names>C</given-names></name><name><surname>Swerdlow</surname> <given-names>DI</given-names></name><name><surname>Tragante</surname> <given-names>V</given-names></name><name><surname>van Iperen</surname> <given-names>EP</given-names></name><name><surname>Sivapalaratnam</surname> <given-names>S</given-names></name><name><surname>Shah</surname> <given-names>S</given-names></name><name><surname>Elbers</surname> <given-names>CC</given-names></name><name><surname>Shah</surname> <given-names>T</given-names></name><name><surname>Engmann</surname> <given-names>J</given-names></name><name><surname>Giambartolomei</surname> <given-names>C</given-names></name><name><surname>White</surname> <given-names>J</given-names></name><name><surname>Zabaneh</surname> <given-names>D</given-names></name><name><surname>Sofat</surname> <given-names>R</given-names></name><name><surname>McLachlan</surname> <given-names>S</given-names></name><name><surname>Doevendans</surname> <given-names>PA</given-names></name><name><surname>Balmforth</surname> <given-names>AJ</given-names></name><name><surname>Hall</surname> <given-names>AS</given-names></name><name><surname>North</surname> <given-names>KE</given-names></name><name><surname>Almoguera</surname> <given-names>B</given-names></name><name><surname>Hoogeveen</surname> <given-names>RC</given-names></name><name><surname>Cushman</surname> <given-names>M</given-names></name><name><surname>Fornage</surname> <given-names>M</given-names></name><name><surname>Patel</surname> <given-names>SR</given-names></name><name><surname>Redline</surname> <given-names>S</given-names></name><name><surname>Siscovick</surname> <given-names>DS</given-names></name><name><surname>Tsai</surname> <given-names>MY</given-names></name><name><surname>Karczewski</surname> <given-names>KJ</given-names></name><name><surname>Hofker</surname> <given-names>MH</given-names></name><name><surname>Verschuren</surname> <given-names>WM</given-names></name><name><surname>Bots</surname> <given-names>ML</given-names></name><name><surname>van der Schouw</surname> <given-names>YT</given-names></name><name><surname>Melander</surname> <given-names>O</given-names></name><name><surname>Dominiczak</surname> <given-names>AF</given-names></name><name><surname>Morris</surname> <given-names>R</given-names></name><name><surname>Ben-Shlomo</surname> <given-names>Y</given-names></name><name><surname>Price</surname> <given-names>J</given-names></name><name><surname>Kumari</surname> <given-names>M</given-names></name><name><surname>Baumert</surname> <given-names>J</given-names></name><name><surname>Peters</surname> <given-names>A</given-names></name><name><surname>Thorand</surname> <given-names>B</given-names></name><name><surname>Koenig</surname> <given-names>W</given-names></name><name><surname>Gaunt</surname> <given-names>TR</given-names></name><name><surname>Humphries</surname> <given-names>SE</given-names></name><name><surname>Clarke</surname> <given-names>R</given-names></name><name><surname>Watkins</surname> <given-names>H</given-names></name><name><surname>Farrall</surname> <given-names>M</given-names></name><name><surname>Wilson</surname> <given-names>JG</given-names></name><name><surname>Rich</surname> <given-names>SS</given-names></name><name><surname>de Bakker</surname> <given-names>PI</given-names></name><name><surname>Lange</surname> <given-names>LA</given-names></name><name><surname>Davey Smith</surname> <given-names>G</given-names></name><name><surname>Reiner</surname> <given-names>AP</given-names></name><name><surname>Talmud</surname> <given-names>PJ</given-names></name><name><surname>KivimÃ¤ki</surname> <given-names>M</given-names></name><name><surname>Lawlor</surname> <given-names>DA</given-names></name><name><surname>Dudbridge</surname> <given-names>F</given-names></name><name><surname>Samani</surname> <given-names>NJ</given-names></name><name><surname>Keating</surname> <given-names>BJ</given-names></name><name><surname>Hingorani</surname> <given-names>AD</given-names></name><name><surname>Casas</surname> <given-names>JP</given-names></name><collab>UCLEB consortium</collab></person-group><year iso-8601-date="2015">2015</year><article-title>Mendelian randomization of blood lipids for coronary heart disease</article-title><source>European Heart Journal</source><volume>36</volume><fpage>539</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/eht571</pub-id><pub-id pub-id-type="pmid">24474739</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holmes</surname> <given-names>MV</given-names></name><name><surname>Millwood</surname> <given-names>IY</given-names></name><name><surname>Kartsonaki</surname> <given-names>C</given-names></name><name><surname>Hill</surname> <given-names>MR</given-names></name><name><surname>Bennett</surname> <given-names>DA</given-names></name><name><surname>Boxall</surname> <given-names>R</given-names></name><name><surname>Guo</surname> <given-names>Y</given-names></name><name><surname>Xu</surname> <given-names>X</given-names></name><name><surname>Bian</surname> <given-names>Z</given-names></name><name><surname>Hu</surname> <given-names>R</given-names></name><name><surname>Walters</surname> <given-names>RG</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Ala-Korpela</surname> <given-names>M</given-names></name><name><surname>Parish</surname> <given-names>S</given-names></name><name><surname>Clarke</surname> <given-names>RJ</given-names></name><name><surname>Peto</surname> <given-names>R</given-names></name><name><surname>Collins</surname> <given-names>R</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Chen</surname> <given-names>Z</given-names></name><collab>China Kadoorie Biobank Collaborative Group</collab></person-group><year iso-8601-date="2018">2018</year><article-title>Lipids, lipoproteins, and metabolites andÂ Risk of Myocardial Infarction andÂ Stroke</article-title><source>Journal of the American College of Cardiology</source><volume>71</volume><fpage>620</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2017.12.006</pub-id><pub-id pub-id-type="pmid">29420958</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inouye</surname> <given-names>M</given-names></name><name><surname>Kettunen</surname> <given-names>J</given-names></name><name><surname>Soininen</surname> <given-names>P</given-names></name><name><surname>Silander</surname> <given-names>K</given-names></name><name><surname>Ripatti</surname> <given-names>S</given-names></name><name><surname>Kumpula</surname> <given-names>LS</given-names></name><name><surname>HÃ¤mÃ¤lÃ¤inen</surname> <given-names>E</given-names></name><name><surname>Jousilahti</surname> <given-names>P</given-names></name><name><surname>Kangas</surname> <given-names>AJ</given-names></name><name><surname>MÃ¤nnistÃ¶</surname> <given-names>S</given-names></name><name><surname>Savolainen</surname> <given-names>MJ</given-names></name><name><surname>Jula</surname> <given-names>A</given-names></name><name><surname>LeiviskÃ¤</surname> <given-names>J</given-names></name><name><surname>Palotie</surname> <given-names>A</given-names></name><name><surname>Salomaa</surname> <given-names>V</given-names></name><name><surname>Perola</surname> <given-names>M</given-names></name><name><surname>Ala-Korpela</surname> <given-names>M</given-names></name><name><surname>Peltonen</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Metabonomic, Transcriptomic, and genomic variation of a population cohort</article-title><source>Molecular Systems Biology</source><volume>6</volume><elocation-id>441</elocation-id><pub-id pub-id-type="doi">10.1038/msb.2010.93</pub-id><pub-id pub-id-type="pmid">21179014</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname> <given-names>WP</given-names></name><name><surname>Wang</surname> <given-names>C</given-names></name><name><surname>Jiang</surname> <given-names>S</given-names></name><name><surname>Pan</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Characteristics of obesity and its related disorders in China</article-title><source>Biomedical and Environmental Sciences</source><volume>23</volume><fpage>4</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/S0895-3988(10)60025-6</pub-id><pub-id pub-id-type="pmid">20486430</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kujala</surname> <given-names>UM</given-names></name><name><surname>MÃ¤kinen</surname> <given-names>VP</given-names></name><name><surname>Heinonen</surname> <given-names>I</given-names></name><name><surname>Soininen</surname> <given-names>P</given-names></name><name><surname>Kangas</surname> <given-names>AJ</given-names></name><name><surname>Leskinen</surname> <given-names>TH</given-names></name><name><surname>Rahkila</surname> <given-names>P</given-names></name><name><surname>WÃ¼rtz</surname> <given-names>P</given-names></name><name><surname>Kovanen</surname> <given-names>V</given-names></name><name><surname>Cheng</surname> <given-names>S</given-names></name><name><surname>SipilÃ¤</surname> <given-names>S</given-names></name><name><surname>Hirvensalo</surname> <given-names>M</given-names></name><name><surname>Telama</surname> <given-names>R</given-names></name><name><surname>Tammelin</surname> <given-names>T</given-names></name><name><surname>Savolainen</surname> <given-names>MJ</given-names></name><name><surname>Pouta</surname> <given-names>A</given-names></name><name><surname>O'Reilly</surname> <given-names>PF</given-names></name><name><surname>MÃ¤ntyselkÃ¤</surname> <given-names>P</given-names></name><name><surname>Viikari</surname> <given-names>J</given-names></name><name><surname>KÃ¤hÃ¶nen</surname> <given-names>M</given-names></name><name><surname>LehtimÃ¤ki</surname> <given-names>T</given-names></name><name><surname>Elliott</surname> <given-names>P</given-names></name><name><surname>Vanhala</surname> <given-names>MJ</given-names></name><name><surname>Raitakari</surname> <given-names>OT</given-names></name><name><surname>JÃ¤rvelin</surname> <given-names>MR</given-names></name><name><surname>Kaprio</surname> <given-names>J</given-names></name><name><surname>Kainulainen</surname> <given-names>H</given-names></name><name><surname>Ala-Korpela</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Long-term leisure-time physical activity and serum metabolome</article-title><source>Circulation</source><volume>127</volume><fpage>340</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.112.105551</pub-id><pub-id pub-id-type="pmid">23258601</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lankinen</surname> <given-names>M</given-names></name><name><surname>Kolehmainen</surname> <given-names>M</given-names></name><name><surname>JÃ¤Ã¤skelÃ¤inen</surname> <given-names>T</given-names></name><name><surname>Paananen</surname> <given-names>J</given-names></name><name><surname>Joukamo</surname> <given-names>L</given-names></name><name><surname>Kangas</surname> <given-names>AJ</given-names></name><name><surname>Soininen</surname> <given-names>P</given-names></name><name><surname>Poutanen</surname> <given-names>K</given-names></name><name><surname>MykkÃ¤nen</surname> <given-names>H</given-names></name><name><surname>Gylling</surname> <given-names>H</given-names></name><name><surname>OreÅ¡iÄ</surname> <given-names>M</given-names></name><name><surname>Jauhiainen</surname> <given-names>M</given-names></name><name><surname>Ala-Korpela</surname> <given-names>M</given-names></name><name><surname>Uusitupa</surname> <given-names>M</given-names></name><name><surname>Schwab</surname> <given-names>U</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Effects of whole grain, fish and bilberries on serum metabolic profile and lipid transfer protein activities: a randomized trial (Sysdimet)</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e90352</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0090352</pub-id><pub-id pub-id-type="pmid">24587337</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Pan</surname> <given-names>A</given-names></name><name><surname>Wang</surname> <given-names>DD</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Dhana</surname> <given-names>K</given-names></name><name><surname>Franco</surname> <given-names>OH</given-names></name><name><surname>Kaptoge</surname> <given-names>S</given-names></name><name><surname>Di Angelantonio</surname> <given-names>E</given-names></name><name><surname>Stampfer</surname> <given-names>M</given-names></name><name><surname>Willett</surname> <given-names>WC</given-names></name><name><surname>Hu</surname> <given-names>FB</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Impact of healthy lifestyle factors on life expectancies in the US population</article-title><source>Circulation</source><volume>138</volume><fpage>345</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.117.032047</pub-id><pub-id pub-id-type="pmid">29712712</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Schoufour</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>DD</given-names></name><name><surname>Dhana</surname> <given-names>K</given-names></name><name><surname>Pan</surname> <given-names>A</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Song</surname> <given-names>M</given-names></name><name><surname>Liu</surname> <given-names>G</given-names></name><name><surname>Shin</surname> <given-names>HJ</given-names></name><name><surname>Sun</surname> <given-names>Q</given-names></name><name><surname>Al-Shaar</surname> <given-names>L</given-names></name><name><surname>Wang</surname> <given-names>M</given-names></name><name><surname>Rimm</surname> <given-names>EB</given-names></name><name><surname>Hertzmark</surname> <given-names>E</given-names></name><name><surname>Stampfer</surname> <given-names>MJ</given-names></name><name><surname>Willett</surname> <given-names>WC</given-names></name><name><surname>Franco</surname> <given-names>OH</given-names></name><name><surname>Hu</surname> <given-names>FB</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Healthy lifestyle and life expectancy free of Cancer, cardiovascular disease, and type 2 diabetes: prospective cohort study</article-title><source>BMJ</source><volume>368</volume><elocation-id>l6669</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.l6669</pub-id><pub-id pub-id-type="pmid">31915124</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lloyd-Jones</surname> <given-names>DM</given-names></name><name><surname>Hong</surname> <given-names>Y</given-names></name><name><surname>Labarthe</surname> <given-names>D</given-names></name><name><surname>Mozaffarian</surname> <given-names>D</given-names></name><name><surname>Appel</surname> <given-names>LJ</given-names></name><name><surname>Van Horn</surname> <given-names>L</given-names></name><name><surname>Greenlund</surname> <given-names>K</given-names></name><name><surname>Daniels</surname> <given-names>S</given-names></name><name><surname>Nichol</surname> <given-names>G</given-names></name><name><surname>Tomaselli</surname> <given-names>GF</given-names></name><name><surname>Arnett</surname> <given-names>DK</given-names></name><name><surname>Fonarow</surname> <given-names>GC</given-names></name><name><surname>Ho</surname> <given-names>PM</given-names></name><name><surname>Lauer</surname> <given-names>MS</given-names></name><name><surname>Masoudi</surname> <given-names>FA</given-names></name><name><surname>Robertson</surname> <given-names>RM</given-names></name><name><surname>Roger</surname> <given-names>V</given-names></name><name><surname>Schwamm</surname> <given-names>LH</given-names></name><name><surname>Sorlie</surname> <given-names>P</given-names></name><name><surname>Yancy</surname> <given-names>CW</given-names></name><name><surname>Rosamond</surname> <given-names>WD</given-names></name><collab>American Heart Association Strategic Planning Task Force and Statistics Committee</collab></person-group><year iso-8601-date="2010">2010</year><article-title>Defining and setting national goals for cardiovascular health promotion and disease reduction: the american heart association's strategic Impact Goal through 2020 and beyond</article-title><source>Circulation</source><volume>121</volume><fpage>586</fpage><lpage>613</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.109.192703</pub-id><pub-id pub-id-type="pmid">20089546</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname> <given-names>J</given-names></name><name><surname>Yu</surname> <given-names>C</given-names></name><name><surname>Guo</surname> <given-names>Y</given-names></name><name><surname>Bian</surname> <given-names>Z</given-names></name><name><surname>Yang</surname> <given-names>L</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Hu</surname> <given-names>X</given-names></name><name><surname>Hou</surname> <given-names>W</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Chen</surname> <given-names>Z</given-names></name><name><surname>Qi</surname> <given-names>L</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><collab>China Kadoorie Biobank Collaborative Group</collab></person-group><year iso-8601-date="2017">2017a</year><article-title>Adherence to a healthy lifestyle and the risk of type 2 diabetes in chinese adults</article-title><source>International Journal of Epidemiology</source><volume>46</volume><fpage>1410</fpage><lpage>1420</lpage><pub-id pub-id-type="doi">10.1093/ije/dyx074</pub-id><pub-id pub-id-type="pmid">28582543</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname> <given-names>J</given-names></name><name><surname>Yu</surname> <given-names>C</given-names></name><name><surname>Guo</surname> <given-names>Y</given-names></name><name><surname>Bian</surname> <given-names>Z</given-names></name><name><surname>Yang</surname> <given-names>L</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Tang</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>W</given-names></name><name><surname>Qian</surname> <given-names>Y</given-names></name><name><surname>Huang</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Chen</surname> <given-names>Z</given-names></name><name><surname>Qi</surname> <given-names>L</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Chen</surname> <given-names>Z</given-names></name><name><surname>Collins</surname> <given-names>R</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Peto</surname> <given-names>R</given-names></name><name><surname>Avery</surname> <given-names>D</given-names></name><name><surname>Boxall</surname> <given-names>R</given-names></name><name><surname>Bennett</surname> <given-names>D</given-names></name><name><surname>Chang</surname> <given-names>Y</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Chen</surname> <given-names>Z</given-names></name><name><surname>Clarke</surname> <given-names>R</given-names></name><name><surname>Du</surname> <given-names>H</given-names></name><name><surname>Gilbert</surname> <given-names>S</given-names></name><name><surname>Hacker</surname> <given-names>A</given-names></name><name><surname>Holmes</surname> <given-names>M</given-names></name><name><surname>Iona</surname> <given-names>A</given-names></name><name><surname>Kartsonaki</surname> <given-names>C</given-names></name><name><surname>Kerosi</surname> <given-names>R</given-names></name><name><surname>Kong</surname> <given-names>L</given-names></name><name><surname>Kurmi</surname> <given-names>O</given-names></name><name><surname>Lancaster</surname> <given-names>G</given-names></name><name><surname>Lewington</surname> <given-names>S</given-names></name><name><surname>Lin</surname> <given-names>K</given-names></name><name><surname>McDonnell</surname> <given-names>J</given-names></name><name><surname>Mei</surname> <given-names>W</given-names></name><name><surname>Millwood</surname> <given-names>I</given-names></name><name><surname>Nie</surname> <given-names>Q</given-names></name><name><surname>Radhakrishnan</surname> <given-names>J</given-names></name><name><surname>Rafiq</surname> <given-names>S</given-names></name><name><surname>Ryder</surname> <given-names>P</given-names></name><name><surname>Sansome</surname> <given-names>S</given-names></name><name><surname>Schmidt</surname> <given-names>D</given-names></name><name><surname>Sherliker</surname> <given-names>P</given-names></name><name><surname>Sohoni</surname> <given-names>R</given-names></name><name><surname>Turnbull</surname> <given-names>I</given-names></name><name><surname>Walters</surname> <given-names>R</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Yang</surname> <given-names>L</given-names></name><name><surname>Yang</surname> <given-names>X</given-names></name><name><surname>Bian</surname> <given-names>Z</given-names></name><name><surname>Chen</surname> <given-names>G</given-names></name><name><surname>Guo</surname> <given-names>Y</given-names></name><name><surname>Han</surname> <given-names>B</given-names></name><name><surname>Hou</surname> <given-names>C</given-names></name><name><surname>Lv</surname> <given-names>J</given-names></name><name><surname>Pei</surname> <given-names>P</given-names></name><name><surname>Qu</surname> <given-names>S</given-names></name><name><surname>Tan</surname> <given-names>Y</given-names></name><name><surname>Yu</surname> <given-names>C</given-names></name><name><surname>Zhou</surname> <given-names>H</given-names></name><name><surname>Pang</surname> <given-names>Z</given-names></name><name><surname>Gao</surname> <given-names>R</given-names></name><name><surname>Wang</surname> <given-names>S</given-names></name><name><surname>Liu</surname> <given-names>Y-M</given-names></name><name><surname>Du</surname> <given-names>Rran</given-names></name><name><surname>Zang</surname> <given-names>Y</given-names></name><name><surname>Cheng</surname> <given-names>L</given-names></name><name><surname>Tian</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Lv</surname> <given-names>S</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Hou</surname> <given-names>W</given-names></name><name><surname>Yin</surname> <given-names>J</given-names></name><name><surname>Jiang</surname> <given-names>G</given-names></name><name><surname>Zhou</surname> <given-names>X</given-names></name><name><surname>Yang</surname> <given-names>L</given-names></name><name><surname>He</surname> <given-names>H</given-names></name><name><surname>Yu</surname> <given-names>B</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Mu</surname> <given-names>H</given-names></name><name><surname>Xu</surname> <given-names>Q</given-names></name><name><surname>Dou</surname> <given-names>M</given-names></name><name><surname>Ren</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>S</given-names></name><name><surname>Hu</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Fu</surname> <given-names>Y</given-names></name><name><surname>Fu</surname> <given-names>Z</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Weng</surname> <given-names>M</given-names></name><name><surname>Zheng</surname> <given-names>X</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Wu</surname> <given-names>M</given-names></name><name><surname>Zhou</surname> <given-names>J</given-names></name><name><surname>Tao</surname> <given-names>R</given-names></name><name><surname>Yang</surname> <given-names>J</given-names></name><name><surname>Ni</surname> <given-names>C</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Hu</surname> <given-names>Y</given-names></name><name><surname>Lu</surname> <given-names>Y</given-names></name><name><surname>Ma</surname> <given-names>L</given-names></name><name><surname>Tang</surname> <given-names>A</given-names></name><name><surname>Zhang</surname> <given-names>S</given-names></name><name><surname>Jin</surname> <given-names>J</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Tang</surname> <given-names>Z</given-names></name><name><surname>Chen</surname> <given-names>N</given-names></name><name><surname>Huang</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>M</given-names></name><name><surname>Meng</surname> <given-names>J</given-names></name><name><surname>Pan</surname> <given-names>R</given-names></name><name><surname>Jiang</surname> <given-names>Q</given-names></name><name><surname>Zhang</surname> <given-names>W</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Wei</surname> <given-names>L</given-names></name><name><surname>Zhou</surname> <given-names>L</given-names></name><name><surname>Chen</surname> <given-names>N</given-names></name><name><surname>Guan</surname> <given-names>H</given-names></name><name><surname>Wu</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>N</given-names></name><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Tang</surname> <given-names>X</given-names></name><name><surname>Luo</surname> <given-names>G</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Zhong</surname> <given-names>X</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Sun</surname> <given-names>Q</given-names></name><name><surname>Ge</surname> <given-names>P</given-names></name><name><surname>Ren</surname> <given-names>X</given-names></name><name><surname>Dong</surname> <given-names>C</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Mao</surname> <given-names>E</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>T</given-names></name><name><surname>zhang</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>D</given-names></name><name><surname>Zhou</surname> <given-names>G</given-names></name><name><surname>Feng</surname> <given-names>S</given-names></name><name><surname>Chang</surname> <given-names>L</given-names></name><name><surname>Fan</surname> <given-names>L</given-names></name><name><surname>Gao</surname> <given-names>Y</given-names></name><name><surname>He</surname> <given-names>T</given-names></name><name><surname>Sun</surname> <given-names>H</given-names></name><name><surname>He</surname> <given-names>P</given-names></name><name><surname>Hu</surname> <given-names>C</given-names></name><name><surname>Lv</surname> <given-names>Q</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Yu</surname> <given-names>M</given-names></name><name><surname>Hu</surname> <given-names>R</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Qian</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>C</given-names></name><name><surname>Xie</surname> <given-names>K</given-names></name><name><surname>Chen</surname> <given-names>L</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Pan</surname> <given-names>D</given-names></name><name><surname>Huang</surname> <given-names>Y</given-names></name><name><surname>Chen</surname> <given-names>B</given-names></name><name><surname>Yin</surname> <given-names>L</given-names></name><name><surname>Jin</surname> <given-names>D</given-names></name><name><surname>Liu</surname> <given-names>H</given-names></name><name><surname>Fu</surname> <given-names>Z</given-names></name><name><surname>Xu</surname> <given-names>Q</given-names></name><name><surname>Xu</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Xiong</surname> <given-names>Y</given-names></name><name><surname>Long</surname> <given-names>H</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Qiu</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2017">2017b</year><article-title>Adherence to Healthy Lifestyle and Cardiovascular Diseases in the ChineseÂ Population</article-title><source>Journal of the American College of Cardiology</source><volume>69</volume><fpage>1116</fpage><lpage>1125</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2016.11.076</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McQueen</surname> <given-names>MJ</given-names></name><name><surname>Hawken</surname> <given-names>S</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Ounpuu</surname> <given-names>S</given-names></name><name><surname>Sniderman</surname> <given-names>A</given-names></name><name><surname>Probstfield</surname> <given-names>J</given-names></name><name><surname>Steyn</surname> <given-names>K</given-names></name><name><surname>Sanderson</surname> <given-names>JE</given-names></name><name><surname>Hasani</surname> <given-names>M</given-names></name><name><surname>Volkova</surname> <given-names>E</given-names></name><name><surname>Kazmi</surname> <given-names>K</given-names></name><name><surname>Yusuf</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study</article-title><source>The Lancet</source><volume>372</volume><fpage>224</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(08)61076-4</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mora</surname> <given-names>S</given-names></name><name><surname>Cook</surname> <given-names>N</given-names></name><name><surname>Buring</surname> <given-names>JE</given-names></name><name><surname>Ridker</surname> <given-names>PM</given-names></name><name><surname>Lee</surname> <given-names>IM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms</article-title><source>Circulation</source><volume>116</volume><fpage>2110</fpage><lpage>2118</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.729939</pub-id><pub-id pub-id-type="pmid">17967770</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Natarajan</surname> <given-names>P</given-names></name><name><surname>Ray</surname> <given-names>KK</given-names></name><name><surname>Cannon</surname> <given-names>CP</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>High-density lipoprotein and coronary heart disease: current and future therapies</article-title><source>Journal of the American College of Cardiology</source><volume>55</volume><fpage>1283</fpage><lpage>1299</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2010.01.008</pub-id><pub-id pub-id-type="pmid">20338488</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peter</surname> <given-names>W</given-names></name><name><surname>Havulinna Aki</surname> <given-names>S</given-names></name><name><surname>Pasi</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Metabolite profiling and cardiovascular event risk</article-title><source>Circulation</source><volume>131</volume><fpage>774</fpage><lpage>785</lpage></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname> <given-names>SA</given-names></name><name><surname>Singhateh</surname> <given-names>Y</given-names></name><name><surname>Mackay</surname> <given-names>D</given-names></name><name><surname>Huxley</surname> <given-names>RR</given-names></name><name><surname>Woodward</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Total cholesterol as a risk factor for coronary heart disease and stroke in women compared with men: a systematic review and meta-analysis</article-title><source>Atherosclerosis</source><volume>248</volume><fpage>123</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2016.03.016</pub-id><pub-id pub-id-type="pmid">27016614</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinkosky</surname> <given-names>SL</given-names></name><name><surname>Newton</surname> <given-names>RS</given-names></name><name><surname>Day</surname> <given-names>EA</given-names></name><name><surname>Ford</surname> <given-names>RJ</given-names></name><name><surname>Lhotak</surname> <given-names>S</given-names></name><name><surname>Austin</surname> <given-names>RC</given-names></name><name><surname>Birch</surname> <given-names>CM</given-names></name><name><surname>Smith</surname> <given-names>BK</given-names></name><name><surname>Filippov</surname> <given-names>S</given-names></name><name><surname>Groot</surname> <given-names>PHE</given-names></name><name><surname>Steinberg</surname> <given-names>GR</given-names></name><name><surname>Lalwani</surname> <given-names>ND</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>13457</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms13457</pub-id><pub-id pub-id-type="pmid">27892461</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roerecke</surname> <given-names>M</given-names></name><name><surname>Rehm</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Alcohol consumption, drinking patterns, and ischemic heart disease: a narrative review of meta-analyses and a systematic review and meta-analysis of the impact of heavy drinking occasions on risk for moderate drinkers</article-title><source>BMC Medicine</source><volume>12</volume><elocation-id>182</elocation-id><pub-id pub-id-type="doi">10.1186/s12916-014-0182-6</pub-id><pub-id pub-id-type="pmid">25567363</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname> <given-names>GA</given-names></name><name><surname>Abate</surname> <given-names>D</given-names></name><name><surname>Abate</surname> <given-names>KH</given-names></name><name><surname>Abay</surname> <given-names>SM</given-names></name><name><surname>Abbafati</surname> <given-names>C</given-names></name><name><surname>Abbasi</surname> <given-names>N</given-names></name><name><surname>Abbastabar</surname> <given-names>H</given-names></name><name><surname>Abd-Allah</surname> <given-names>F</given-names></name><name><surname>Abdela</surname> <given-names>J</given-names></name><name><surname>Abdelalim</surname> <given-names>A</given-names></name><name><surname>Abdollahpour</surname> <given-names>I</given-names></name><name><surname>Abdulkader</surname> <given-names>RS</given-names></name><name><surname>Abebe</surname> <given-names>HT</given-names></name><name><surname>Abebe</surname> <given-names>M</given-names></name><name><surname>Abebe</surname> <given-names>Z</given-names></name><name><surname>Abejie</surname> <given-names>AN</given-names></name><name><surname>Abera</surname> <given-names>SF</given-names></name><name><surname>Abil</surname> <given-names>OZ</given-names></name><name><surname>Abraha</surname> <given-names>HN</given-names></name><name><surname>Abrham</surname> <given-names>AR</given-names></name><name><surname>Abu-Raddad</surname> <given-names>LJ</given-names></name><name><surname>Accrombessi</surname> <given-names>MMK</given-names></name><name><surname>Acharya</surname> <given-names>D</given-names></name><name><surname>Adamu</surname> <given-names>AA</given-names></name><name><surname>Adebayo</surname> <given-names>OM</given-names></name><name><surname>Adedoyin</surname> <given-names>RA</given-names></name><name><surname>Adekanmbi</surname> <given-names>V</given-names></name><name><surname>Adetokunboh</surname> <given-names>OO</given-names></name><name><surname>Adhena</surname> <given-names>BM</given-names></name><name><surname>Adib</surname> <given-names>MG</given-names></name><name><surname>Admasie</surname> <given-names>A</given-names></name><name><surname>Afshin</surname> <given-names>A</given-names></name><name><surname>Agarwal</surname> <given-names>G</given-names></name><name><surname>Agesa</surname> <given-names>KM</given-names></name><name><surname>Agrawal</surname> <given-names>A</given-names></name><name><surname>Agrawal</surname> <given-names>S</given-names></name><name><surname>Ahmadi</surname> <given-names>A</given-names></name><name><surname>Ahmadi</surname> <given-names>M</given-names></name><name><surname>Ahmed</surname> <given-names>MB</given-names></name><name><surname>Ahmed</surname> <given-names>S</given-names></name><name><surname>Aichour</surname> <given-names>AN</given-names></name><name><surname>Aichour</surname> <given-names>I</given-names></name><name><surname>Aichour</surname> <given-names>MTE</given-names></name><name><surname>Akbari</surname> <given-names>ME</given-names></name><name><surname>Akinyemi</surname> <given-names>RO</given-names></name><name><surname>Akseer</surname> <given-names>N</given-names></name><name><surname>Al-Aly</surname> <given-names>Z</given-names></name><name><surname>Al-Eyadhy</surname> <given-names>A</given-names></name><name><surname>Al-Raddadi</surname> <given-names>RM</given-names></name><name><surname>Alahdab</surname> <given-names>F</given-names></name><name><surname>Alam</surname> <given-names>K</given-names></name><name><surname>Alam</surname> <given-names>T</given-names></name><name><surname>Alebel</surname> <given-names>A</given-names></name><name><surname>Alene</surname> <given-names>KA</given-names></name><name><surname>Alijanzadeh</surname> <given-names>M</given-names></name><name><surname>Alizadeh-Navaei</surname> <given-names>R</given-names></name><name><surname>Aljunid</surname> <given-names>SM</given-names></name><name><surname>Alkerwi</surname> <given-names>A</given-names></name><name><surname>Alla</surname> <given-names>F</given-names></name><name><surname>Allebeck</surname> <given-names>P</given-names></name><name><surname>Alonso</surname> <given-names>J</given-names></name><name><surname>Altirkawi</surname> <given-names>K</given-names></name><name><surname>Alvis-Guzman</surname> <given-names>N</given-names></name><name><surname>Amare</surname> <given-names>AT</given-names></name><name><surname>Aminde</surname> <given-names>LN</given-names></name><name><surname>Amini</surname> <given-names>E</given-names></name><name><surname>Ammar</surname> <given-names>W</given-names></name><name><surname>Amoako</surname> <given-names>YA</given-names></name><name><surname>Anber</surname> <given-names>NH</given-names></name><name><surname>Andrei</surname> <given-names>CL</given-names></name><name><surname>Androudi</surname> <given-names>S</given-names></name><name><surname>Animut</surname> <given-names>MD</given-names></name><name><surname>Anjomshoa</surname> <given-names>M</given-names></name><name><surname>Ansari</surname> <given-names>H</given-names></name><name><surname>Ansha</surname> <given-names>MG</given-names></name><name><surname>Antonio</surname> <given-names>CAT</given-names></name><name><surname>Anwari</surname> <given-names>P</given-names></name><name><surname>Aremu</surname> <given-names>O</given-names></name><name><surname>ÃrnlÃ¶v</surname> <given-names>J</given-names></name><name><surname>Arora</surname> <given-names>A</given-names></name><name><surname>Arora</surname> <given-names>M</given-names></name><name><surname>Artaman</surname> <given-names>A</given-names></name><name><surname>Aryal</surname> <given-names>KK</given-names></name><name><surname>Asayesh</surname> <given-names>H</given-names></name><name><surname>Asfaw</surname> <given-names>ET</given-names></name><name><surname>Ataro</surname> <given-names>Z</given-names></name><name><surname>Atique</surname> <given-names>S</given-names></name><name><surname>Atre</surname> <given-names>SR</given-names></name><name><surname>Ausloos</surname> <given-names>M</given-names></name><name><surname>Avokpaho</surname> <given-names>EFGA</given-names></name><name><surname>Awasthi</surname> <given-names>A</given-names></name><name><surname>Quintanilla</surname> <given-names>BPA</given-names></name><name><surname>Ayele</surname> <given-names>Y</given-names></name><name><surname>Ayer</surname> <given-names>R</given-names></name><name><surname>Azzopardi</surname> <given-names>PS</given-names></name><name><surname>Babazadeh</surname> <given-names>A</given-names></name><name><surname>Bacha</surname> <given-names>U</given-names></name><name><surname>Badali</surname> <given-names>H</given-names></name><name><surname>Badawi</surname> <given-names>A</given-names></name><name><surname>Bali</surname> <given-names>AG</given-names></name><name><surname>Ballesteros</surname> <given-names>KE</given-names></name><name><surname>Banach</surname> <given-names>M</given-names></name><name><surname>Banerjee</surname> <given-names>K</given-names></name><name><surname>Bannick</surname> <given-names>MS</given-names></name><name><surname>Banoub</surname> <given-names>JAM</given-names></name><name><surname>Barboza</surname> <given-names>MA</given-names></name><name><surname>Barker-Collo</surname> <given-names>SL</given-names></name><name><surname>BÃ¤rnighausen</surname> <given-names>TW</given-names></name><name><surname>Barquera</surname> <given-names>S</given-names></name><name><surname>Barrero</surname> <given-names>LH</given-names></name><name><surname>Bassat</surname> <given-names>Q</given-names></name><name><surname>Basu</surname> <given-names>S</given-names></name><name><surname>Baune</surname> <given-names>BT</given-names></name><name><surname>Baynes</surname> <given-names>HW</given-names></name><name><surname>Bazargan-Hejazi</surname> <given-names>S</given-names></name><name><surname>Bedi</surname> <given-names>N</given-names></name><name><surname>Beghi</surname> <given-names>E</given-names></name><name><surname>Behzadifar</surname> <given-names>M</given-names></name><name><surname>Behzadifar</surname> <given-names>M</given-names></name><name><surname>BÃ©jot</surname> <given-names>Y</given-names></name><name><surname>Bekele</surname> <given-names>BB</given-names></name><name><surname>Belachew</surname> <given-names>AB</given-names></name><name><surname>Belay</surname> <given-names>E</given-names></name><name><surname>Belay</surname> <given-names>YA</given-names></name><name><surname>Bell</surname> <given-names>ML</given-names></name><name><surname>Bello</surname> <given-names>AK</given-names></name><name><surname>Bennett</surname> <given-names>DA</given-names></name><name><surname>Bensenor</surname> <given-names>IM</given-names></name><name><surname>Berman</surname> <given-names>AE</given-names></name><name><surname>Bernabe</surname> <given-names>E</given-names></name><name><surname>Bernstein</surname> <given-names>RS</given-names></name><name><surname>Bertolacci</surname> <given-names>GJ</given-names></name><name><surname>Beuran</surname> <given-names>M</given-names></name><name><surname>Beyranvand</surname> <given-names>T</given-names></name><name><surname>Bhalla</surname> <given-names>A</given-names></name><name><surname>Bhattarai</surname> <given-names>S</given-names></name><name><surname>Bhaumik</surname> <given-names>S</given-names></name><name><surname>Bhutta</surname> <given-names>ZA</given-names></name><name><surname>Biadgo</surname> <given-names>B</given-names></name><name><surname>Biehl</surname> <given-names>MH</given-names></name><name><surname>Bijani</surname> <given-names>A</given-names></name><name><surname>Bikbov</surname> <given-names>B</given-names></name><name><surname>Bilano</surname> <given-names>V</given-names></name><name><surname>Bililign</surname> <given-names>N</given-names></name><name><surname>Bin Sayeed</surname> <given-names>MS</given-names></name><name><surname>Bisanzio</surname> <given-names>D</given-names></name><name><surname>Biswas</surname> <given-names>T</given-names></name><name><surname>Blacker</surname> <given-names>BF</given-names></name><name><surname>Basara</surname> <given-names>BB</given-names></name><name><surname>Borschmann</surname> <given-names>R</given-names></name><name><surname>Bosetti</surname> <given-names>C</given-names></name><name><surname>Bozorgmehr</surname> <given-names>K</given-names></name><name><surname>Brady</surname> <given-names>OJ</given-names></name><name><surname>Brant</surname> <given-names>LC</given-names></name><name><surname>Brayne</surname> <given-names>C</given-names></name><name><surname>Brazinova</surname> <given-names>A</given-names></name><name><surname>Breitborde</surname> <given-names>NJK</given-names></name><name><surname>Brenner</surname> <given-names>H</given-names></name><name><surname>Briant</surname> <given-names>PS</given-names></name><name><surname>Britton</surname> <given-names>G</given-names></name><name><surname>Brugha</surname> <given-names>T</given-names></name><name><surname>Busse</surname> <given-names>R</given-names></name><name><surname>Butt</surname> <given-names>ZA</given-names></name><name><surname>Callender</surname> <given-names>CSKH</given-names></name><name><surname>Campos-Nonato</surname> <given-names>IR</given-names></name><name><surname>Campuzano Rincon</surname> <given-names>JC</given-names></name><name><surname>Cano</surname> <given-names>J</given-names></name><name><surname>Car</surname> <given-names>M</given-names></name><name><surname>CÃ¡rdenas</surname> <given-names>R</given-names></name><name><surname>Carreras</surname> <given-names>G</given-names></name><name><surname>Carrero</surname> <given-names>JJ</given-names></name><name><surname>Carter</surname> <given-names>A</given-names></name><name><surname>Carvalho</surname> <given-names>F</given-names></name><name><surname>CastaÃ±eda-Orjuela</surname> <given-names>CA</given-names></name><name><surname>Castillo Rivas</surname> <given-names>J</given-names></name><name><surname>Castle</surname> <given-names>CD</given-names></name><name><surname>Castro</surname> <given-names>C</given-names></name><name><surname>Castro</surname> <given-names>F</given-names></name><name><surname>CatalÃ¡-LÃ³pez</surname> <given-names>F</given-names></name><name><surname>Cerin</surname> <given-names>E</given-names></name><name><surname>Chaiah</surname> <given-names>Y</given-names></name><name><surname>Chang</surname> <given-names>J-C</given-names></name><name><surname>Charlson</surname> <given-names>FJ</given-names></name><name><surname>Chaturvedi</surname> <given-names>P</given-names></name><name><surname>Chiang</surname> <given-names>PP-C</given-names></name><name><surname>Chimed-Ochir</surname> <given-names>O</given-names></name><name><surname>Chisumpa</surname> <given-names>VH</given-names></name><name><surname>Chitheer</surname> <given-names>A</given-names></name><name><surname>Chowdhury</surname> <given-names>R</given-names></name><name><surname>Christensen</surname> <given-names>H</given-names></name><name><surname>Christopher</surname> <given-names>DJ</given-names></name><name><surname>Chung</surname> <given-names>S-C</given-names></name><name><surname>Cicuttini</surname> <given-names>FM</given-names></name><name><surname>Ciobanu</surname> <given-names>LG</given-names></name><name><surname>Cirillo</surname> <given-names>M</given-names></name><name><surname>Cohen</surname> <given-names>AJ</given-names></name><name><surname>Cooper</surname> <given-names>LT</given-names></name><name><surname>Cortesi</surname> <given-names>PA</given-names></name><name><surname>Cortinovis</surname> <given-names>M</given-names></name><name><surname>Cousin</surname> <given-names>E</given-names></name><name><surname>Cowie</surname> <given-names>BC</given-names></name><name><surname>Criqui</surname> <given-names>MH</given-names></name><name><surname>Cromwell</surname> <given-names>EA</given-names></name><name><surname>Crowe</surname> <given-names>CS</given-names></name><name><surname>Crump</surname> <given-names>JA</given-names></name><name><surname>Cunningham</surname> <given-names>M</given-names></name><name><surname>Daba</surname> <given-names>AK</given-names></name><name><surname>Dadi</surname> <given-names>AF</given-names></name><name><surname>Dandona</surname> <given-names>L</given-names></name><name><surname>Dandona</surname> <given-names>R</given-names></name><name><surname>Dang</surname> <given-names>AK</given-names></name><name><surname>Dargan</surname> <given-names>PI</given-names></name><name><surname>Daryani</surname> <given-names>A</given-names></name><name><surname>Das</surname> <given-names>SK</given-names></name><name><surname>Gupta</surname> <given-names>RD</given-names></name><name><surname>Neves</surname> <given-names>JD</given-names></name><name><surname>Dasa</surname> <given-names>TT</given-names></name><name><surname>Dash</surname> <given-names>AP</given-names></name><name><surname>Davis</surname> <given-names>AC</given-names></name><name><surname>Davis Weaver</surname> <given-names>N</given-names></name><name><surname>Davitoiu</surname> <given-names>DV</given-names></name><name><surname>Davletov</surname> <given-names>K</given-names></name><name><surname>De La Hoz</surname> <given-names>FP</given-names></name><name><surname>De Neve</surname> <given-names>J-W</given-names></name><name><surname>Degefa</surname> <given-names>MG</given-names></name><name><surname>Degenhardt</surname> <given-names>L</given-names></name><name><surname>Degfie</surname> <given-names>TT</given-names></name><name><surname>Deiparine</surname> <given-names>S</given-names></name><name><surname>Demoz</surname> <given-names>GT</given-names></name><name><surname>Demtsu</surname> <given-names>BB</given-names></name><name><surname>Denova-GutiÃ©rrez</surname> <given-names>E</given-names></name><name><surname>Deribe</surname> <given-names>K</given-names></name><name><surname>Dervenis</surname> <given-names>N</given-names></name><name><surname>Des Jarlais</surname> <given-names>DC</given-names></name><name><surname>Dessie</surname> <given-names>GA</given-names></name><name><surname>Dey</surname> <given-names>S</given-names></name><name><surname>Dharmaratne</surname> <given-names>SD</given-names></name><name><surname>Dicker</surname> <given-names>D</given-names></name><name><surname>Dinberu</surname> <given-names>MT</given-names></name><name><surname>Ding</surname> <given-names>EL</given-names></name><name><surname>Dirac</surname> <given-names>MA</given-names></name><name><surname>Djalalinia</surname> <given-names>S</given-names></name><name><surname>Dokova</surname> <given-names>K</given-names></name><name><surname>Doku</surname> <given-names>DT</given-names></name><name><surname>Donnelly</surname> <given-names>CA</given-names></name><name><surname>Dorsey</surname> <given-names>ER</given-names></name><name><surname>Doshi</surname> <given-names>PP</given-names></name><name><surname>Douwes-Schultz</surname> <given-names>D</given-names></name><name><surname>Doyle</surname> <given-names>KE</given-names></name><name><surname>Driscoll</surname> <given-names>TR</given-names></name><name><surname>Dubey</surname> <given-names>M</given-names></name><name><surname>Dubljanin</surname> <given-names>E</given-names></name><name><surname>Duken</surname> <given-names>EE</given-names></name><name><surname>Duncan</surname> <given-names>BB</given-names></name><name><surname>Duraes</surname> <given-names>AR</given-names></name><name><surname>Ebrahimi</surname> <given-names>H</given-names></name><name><surname>Ebrahimpour</surname> <given-names>S</given-names></name><name><surname>Edessa</surname> <given-names>D</given-names></name><name><surname>Edvardsson</surname> <given-names>D</given-names></name><name><surname>Eggen</surname> <given-names>AE</given-names></name><name><surname>El Bcheraoui</surname> <given-names>C</given-names></name><name><surname>El Sayed Zaki</surname> <given-names>M</given-names></name><name><surname>El-Khatib</surname> <given-names>Z</given-names></name><name><surname>Elkout</surname> <given-names>H</given-names></name><name><surname>Ellingsen</surname> <given-names>CL</given-names></name><name><surname>Endres</surname> <given-names>M</given-names></name><name><surname>Endries</surname> <given-names>AY</given-names></name><name><surname>Er</surname> <given-names>B</given-names></name><name><surname>Erskine</surname> <given-names>HE</given-names></name><name><surname>Eshrati</surname> <given-names>B</given-names></name><name><surname>Eskandarieh</surname> <given-names>S</given-names></name><name><surname>Esmaeili</surname> <given-names>R</given-names></name><name><surname>Esteghamati</surname> <given-names>A</given-names></name><name><surname>Fakhar</surname> <given-names>M</given-names></name><name><surname>Fakhim</surname> <given-names>H</given-names></name><name><surname>Faramarzi</surname> <given-names>M</given-names></name><name><surname>Fareed</surname> <given-names>M</given-names></name><name><surname>Farhadi</surname> <given-names>F</given-names></name><name><surname>Farinha</surname> <given-names>CSE</given-names></name><name><surname>Faro</surname> <given-names>A</given-names></name><name><surname>Farvid</surname> <given-names>MS</given-names></name><name><surname>Farzadfar</surname> <given-names>F</given-names></name><name><surname>Farzaei</surname> <given-names>MH</given-names></name><name><surname>Feigin</surname> <given-names>VL</given-names></name><name><surname>Feigl</surname> <given-names>AB</given-names></name><name><surname>Fentahun</surname> <given-names>N</given-names></name><name><surname>Fereshtehnejad</surname> <given-names>S-M</given-names></name><name><surname>Fernandes</surname> <given-names>E</given-names></name><name><surname>Fernandes</surname> <given-names>JC</given-names></name><name><surname>Ferrari</surname> <given-names>AJ</given-names></name><name><surname>Feyissa</surname> <given-names>GT</given-names></name><name><surname>Filip</surname> <given-names>I</given-names></name><name><surname>Finegold</surname> <given-names>S</given-names></name><name><surname>Fischer</surname> <given-names>F</given-names></name><name><surname>Fitzmaurice</surname> <given-names>C</given-names></name><name><surname>Foigt</surname> <given-names>NA</given-names></name><name><surname>Foreman</surname> <given-names>KJ</given-names></name><name><surname>Fornari</surname> <given-names>C</given-names></name><name><surname>Frank</surname> <given-names>TD</given-names></name><name><surname>Fukumoto</surname> <given-names>T</given-names></name><name><surname>Fuller</surname> <given-names>JE</given-names></name><name><surname>Fullman</surname> <given-names>N</given-names></name><name><surname>FÃ¼rst</surname> <given-names>T</given-names></name><name><surname>Furtado</surname> <given-names>JM</given-names></name><name><surname>Futran</surname> <given-names>ND</given-names></name><name><surname>Gallus</surname> <given-names>S</given-names></name><name><surname>Garcia-Basteiro</surname> <given-names>AL</given-names></name><name><surname>Garcia-Gordillo</surname> <given-names>MA</given-names></name><name><surname>Gardner</surname> <given-names>WM</given-names></name><name><surname>Gebre</surname> <given-names>AK</given-names></name><name><surname>Gebrehiwot</surname> <given-names>TT</given-names></name><name><surname>Gebremedhin</surname> <given-names>AT</given-names></name><name><surname>Gebremichael</surname> <given-names>B</given-names></name><name><surname>Gebremichael</surname> <given-names>TG</given-names></name><name><surname>Gelano</surname> <given-names>TF</given-names></name><name><surname>Geleijnse</surname> <given-names>JM</given-names></name><name><surname>Genova-Maleras</surname> <given-names>R</given-names></name><name><surname>Geramo</surname> <given-names>YCD</given-names></name><name><surname>Gething</surname> <given-names>PW</given-names></name><name><surname>Gezae</surname> <given-names>KE</given-names></name><name><surname>Ghadami</surname> <given-names>MR</given-names></name><name><surname>Ghadimi</surname> <given-names>R</given-names></name><name><surname>Ghasemi Falavarjani</surname> <given-names>K</given-names></name><name><surname>Ghasemi-Kasman</surname> <given-names>M</given-names></name><name><surname>Ghimire</surname> <given-names>M</given-names></name><name><surname>Gibney</surname> <given-names>KB</given-names></name><name><surname>Gill</surname> <given-names>PS</given-names></name><name><surname>Gill</surname> <given-names>TK</given-names></name><name><surname>Gillum</surname> <given-names>RF</given-names></name><name><surname>Ginawi</surname> <given-names>IA</given-names></name><name><surname>Giroud</surname> <given-names>M</given-names></name><name><surname>Giussani</surname> <given-names>G</given-names></name><name><surname>Goenka</surname> <given-names>S</given-names></name><name><surname>Goldberg</surname> <given-names>EM</given-names></name><name><surname>Goli</surname> <given-names>S</given-names></name><name><surname>GÃ³mez-DantÃ©s</surname> <given-names>H</given-names></name><name><surname>Gona</surname> <given-names>PN</given-names></name><name><surname>Gopalani</surname> <given-names>SV</given-names></name><name><surname>Gorman</surname> <given-names>TM</given-names></name><name><surname>Goto</surname> <given-names>A</given-names></name><name><surname>Goulart</surname> <given-names>AC</given-names></name><name><surname>Gnedovskaya</surname> <given-names>EV</given-names></name><name><surname>Grada</surname> <given-names>A</given-names></name><name><surname>Grosso</surname> <given-names>G</given-names></name><name><surname>Gugnani</surname> <given-names>HC</given-names></name><name><surname>Guimaraes</surname> <given-names>ALS</given-names></name><name><surname>Guo</surname> <given-names>Y</given-names></name><name><surname>Gupta</surname> <given-names>PC</given-names></name><name><surname>Gupta</surname> <given-names>R</given-names></name><name><surname>Gupta</surname> <given-names>R</given-names></name><name><surname>Gupta</surname> <given-names>T</given-names></name><name><surname>GutiÃ©rrez</surname> <given-names>RA</given-names></name><name><surname>Gyawali</surname> <given-names>B</given-names></name><name><surname>Haagsma</surname> <given-names>JA</given-names></name><name><surname>Hafezi-Nejad</surname> <given-names>N</given-names></name><name><surname>Hagos</surname> <given-names>TB</given-names></name><name><surname>Hailegiyorgis</surname> <given-names>TT</given-names></name><name><surname>Hailu</surname> <given-names>GB</given-names></name><name><surname>Haj-Mirzaian</surname> <given-names>A</given-names></name><name><surname>Haj-Mirzaian</surname> <given-names>A</given-names></name><name><surname>Hamadeh</surname> <given-names>RR</given-names></name><name><surname>Hamidi</surname> <given-names>S</given-names></name><name><surname>Handal</surname> <given-names>AJ</given-names></name><name><surname>Hankey</surname> <given-names>GJ</given-names></name><name><surname>Harb</surname> <given-names>HL</given-names></name><name><surname>Harikrishnan</surname> <given-names>S</given-names></name><name><surname>Haro</surname> <given-names>JM</given-names></name><name><surname>Hasan</surname> <given-names>M</given-names></name><name><surname>Hassankhani</surname> <given-names>H</given-names></name><name><surname>Hassen</surname> <given-names>HY</given-names></name><name><surname>Havmoeller</surname> <given-names>R</given-names></name><name><surname>Hay</surname> <given-names>RJ</given-names></name><name><surname>Hay</surname> <given-names>SI</given-names></name><name><surname>He</surname> <given-names>Y</given-names></name><name><surname>Hedayatizadeh-Omran</surname> <given-names>A</given-names></name><name><surname>Hegazy</surname> <given-names>MI</given-names></name><name><surname>Heibati</surname> <given-names>B</given-names></name><name><surname>Heidari</surname> <given-names>M</given-names></name><name><surname>Hendrie</surname> <given-names>D</given-names></name><name><surname>Henok</surname> <given-names>A</given-names></name><name><surname>Henry</surname> <given-names>NJ</given-names></name><name><surname>Herteliu</surname> <given-names>C</given-names></name><name><surname>Heydarpour</surname> <given-names>F</given-names></name><name><surname>Heydarpour</surname> <given-names>P</given-names></name><name><surname>Heydarpour</surname> <given-names>S</given-names></name><name><surname>Hibstu</surname> <given-names>DT</given-names></name><name><surname>Hoek</surname> <given-names>HW</given-names></name><name><surname>Hole</surname> <given-names>MK</given-names></name><name><surname>Homaie Rad</surname> <given-names>E</given-names></name><name><surname>Hoogar</surname> <given-names>P</given-names></name><name><surname>Hosgood</surname> <given-names>HD</given-names></name><name><surname>Hosseini</surname> <given-names>SM</given-names></name><name><surname>Hosseinzadeh</surname> <given-names>M</given-names></name><name><surname>Hostiuc</surname> <given-names>M</given-names></name><name><surname>Hostiuc</surname> <given-names>S</given-names></name><name><surname>Hotez</surname> <given-names>PJ</given-names></name><name><surname>Hoy</surname> <given-names>DG</given-names></name><name><surname>Hsiao</surname> <given-names>T</given-names></name><name><surname>Hu</surname> <given-names>G</given-names></name><name><surname>Huang</surname> <given-names>JJ</given-names></name><name><surname>Husseini</surname> <given-names>A</given-names></name><name><surname>Hussen</surname> <given-names>MM</given-names></name><name><surname>Hutfless</surname> <given-names>S</given-names></name><name><surname>Idrisov</surname> <given-names>B</given-names></name><name><surname>Ilesanmi</surname> <given-names>OS</given-names></name><name><surname>Iqbal</surname> <given-names>U</given-names></name><name><surname>Irvani</surname> <given-names>SSN</given-names></name><name><surname>Irvine</surname> <given-names>CMS</given-names></name><name><surname>Islam</surname> <given-names>N</given-names></name><name><surname>Islam</surname> <given-names>SMS</given-names></name><name><surname>Islami</surname> <given-names>F</given-names></name><name><surname>Jacobsen</surname> <given-names>KH</given-names></name><name><surname>Jahangiry</surname> <given-names>L</given-names></name><name><surname>Jahanmehr</surname> <given-names>N</given-names></name><name><surname>Jain</surname> <given-names>SK</given-names></name><name><surname>Jakovljevic</surname> <given-names>M</given-names></name><name><surname>Jalu</surname> <given-names>MT</given-names></name><name><surname>James</surname> <given-names>SL</given-names></name><name><surname>Javanbakht</surname> <given-names>M</given-names></name><name><surname>Jayatilleke</surname> <given-names>AU</given-names></name><name><surname>Jeemon</surname> <given-names>P</given-names></name><name><surname>Jenkins</surname> <given-names>KJ</given-names></name><name><surname>Jha</surname> <given-names>RP</given-names></name><name><surname>Jha</surname> <given-names>V</given-names></name><name><surname>Johnson</surname> <given-names>CO</given-names></name><name><surname>Johnson</surname> <given-names>SC</given-names></name><name><surname>Jonas</surname> <given-names>JB</given-names></name><name><surname>Joshi</surname> <given-names>A</given-names></name><name><surname>Jozwiak</surname> <given-names>JJ</given-names></name><name><surname>Jungari</surname> <given-names>SB</given-names></name><name><surname>JÃ¼risson</surname> <given-names>M</given-names></name><name><surname>Kabir</surname> <given-names>Z</given-names></name><name><surname>Kadel</surname> <given-names>R</given-names></name><name><surname>Kahsay</surname> <given-names>A</given-names></name><name><surname>Kalani</surname> <given-names>R</given-names></name><name><surname>Karami</surname> <given-names>M</given-names></name><name><surname>Karami Matin</surname> <given-names>B</given-names></name><name><surname>Karch</surname> <given-names>A</given-names></name><name><surname>Karema</surname> <given-names>C</given-names></name><name><surname>Karimi-Sari</surname> <given-names>H</given-names></name><name><surname>Kasaeian</surname> <given-names>A</given-names></name><name><surname>Kassa</surname> <given-names>DH</given-names></name><name><surname>Kassa</surname> <given-names>GM</given-names></name><name><surname>Kassa</surname> <given-names>TD</given-names></name><name><surname>Kassebaum</surname> <given-names>NJ</given-names></name><name><surname>Katikireddi</surname> <given-names>SV</given-names></name><name><surname>Kaul</surname> <given-names>A</given-names></name><name><surname>Kazemi</surname> <given-names>Z</given-names></name><name><surname>Karyani</surname> <given-names>AK</given-names></name><name><surname>Kazi</surname> <given-names>DS</given-names></name><name><surname>Kefale</surname> <given-names>AT</given-names></name><name><surname>Keiyoro</surname> <given-names>PN</given-names></name><name><surname>Kemp</surname> <given-names>GR</given-names></name><name><surname>Kengne</surname> <given-names>AP</given-names></name><name><surname>Keren</surname> <given-names>A</given-names></name><name><surname>Kesavachandran</surname> <given-names>CN</given-names></name><name><surname>Khader</surname> <given-names>YS</given-names></name><name><surname>Khafaei</surname> <given-names>B</given-names></name><name><surname>Khafaie</surname> <given-names>MA</given-names></name><name><surname>Khajavi</surname> <given-names>A</given-names></name><name><surname>Khalid</surname> <given-names>N</given-names></name><name><surname>Khalil</surname> <given-names>IA</given-names></name><name><surname>Khan</surname> <given-names>EA</given-names></name><name><surname>Khan</surname> <given-names>MS</given-names></name><name><surname>Khan</surname> <given-names>MA</given-names></name><name><surname>Khang</surname> <given-names>Y-H</given-names></name><name><surname>Khater</surname> <given-names>MM</given-names></name><name><surname>Khoja</surname> <given-names>AT</given-names></name><name><surname>Khosravi</surname> <given-names>A</given-names></name><name><surname>Khosravi</surname> <given-names>MH</given-names></name><name><surname>Khubchandani</surname> <given-names>J</given-names></name><name><surname>Kiadaliri</surname> <given-names>AA</given-names></name><name><surname>Kibret</surname> <given-names>GD</given-names></name><name><surname>Kidanemariam</surname> <given-names>ZT</given-names></name><name><surname>Kiirithio</surname> <given-names>DN</given-names></name><name><surname>Kim</surname> <given-names>D</given-names></name><name><surname>Kim</surname> <given-names>Y-E</given-names></name><name><surname>Kim</surname> <given-names>YJ</given-names></name><name><surname>Kimokoti</surname> <given-names>RW</given-names></name><name><surname>Kinfu</surname> <given-names>Y</given-names></name><name><surname>Kisa</surname> <given-names>A</given-names></name><name><surname>Kissimova-Skarbek</surname> <given-names>K</given-names></name><name><surname>KivimÃ¤ki</surname> <given-names>M</given-names></name><name><surname>Knudsen</surname> <given-names>AKS</given-names></name><name><surname>Kocarnik</surname> <given-names>JM</given-names></name><name><surname>Kochhar</surname> <given-names>S</given-names></name><name><surname>Kokubo</surname> <given-names>Y</given-names></name><name><surname>Kolola</surname> <given-names>T</given-names></name><name><surname>Kopec</surname> <given-names>JA</given-names></name><name><surname>Koul</surname> <given-names>PA</given-names></name><name><surname>Koyanagi</surname> <given-names>A</given-names></name><name><surname>Kravchenko</surname> <given-names>MA</given-names></name><name><surname>Krishan</surname> <given-names>K</given-names></name><name><surname>Kuate Defo</surname> <given-names>B</given-names></name><name><surname>Kucuk Bicer</surname> <given-names>B</given-names></name><name><surname>Kumar</surname> <given-names>GA</given-names></name><name><surname>Kumar</surname> <given-names>M</given-names></name><name><surname>Kumar</surname> <given-names>P</given-names></name><name><surname>Kutz</surname> <given-names>MJ</given-names></name><name><surname>Kuzin</surname> <given-names>I</given-names></name><name><surname>Kyu</surname> <given-names>HH</given-names></name><name><surname>Lad</surname> <given-names>DP</given-names></name><name><surname>Lad</surname> <given-names>SD</given-names></name><name><surname>Lafranconi</surname> <given-names>A</given-names></name><name><surname>Lal</surname> <given-names>DK</given-names></name><name><surname>Lalloo</surname> <given-names>R</given-names></name><name><surname>Lallukka</surname> <given-names>T</given-names></name><name><surname>Lam</surname> <given-names>JO</given-names></name><name><surname>Lami</surname> <given-names>FH</given-names></name><name><surname>Lansingh</surname> <given-names>VC</given-names></name><name><surname>Lansky</surname> <given-names>S</given-names></name><name><surname>Larson</surname> <given-names>HJ</given-names></name><name><surname>Latifi</surname> <given-names>A</given-names></name><name><surname>Lau</surname> <given-names>KM-M</given-names></name><name><surname>Lazarus</surname> <given-names>JV</given-names></name><name><surname>Lebedev</surname> <given-names>G</given-names></name><name><surname>Lee</surname> <given-names>PH</given-names></name><name><surname>Leigh</surname> <given-names>J</given-names></name><name><surname>Leili</surname> <given-names>M</given-names></name><name><surname>Leshargie</surname> <given-names>CT</given-names></name><name><surname>Li</surname> <given-names>S</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Liang</surname> <given-names>J</given-names></name><name><surname>Lim</surname> <given-names>L-L</given-names></name><name><surname>Lim</surname> <given-names>SS</given-names></name><name><surname>Limenih</surname> <given-names>MA</given-names></name><name><surname>Linn</surname> <given-names>S</given-names></name><name><surname>Liu</surname> <given-names>S</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Lodha</surname> <given-names>R</given-names></name><name><surname>Lonsdale</surname> <given-names>C</given-names></name><name><surname>Lopez</surname> <given-names>AD</given-names></name><name><surname>Lorkowski</surname> <given-names>S</given-names></name><name><surname>Lotufo</surname> <given-names>PA</given-names></name><name><surname>Lozano</surname> <given-names>R</given-names></name><name><surname>Lunevicius</surname> <given-names>R</given-names></name><name><surname>Ma</surname> <given-names>S</given-names></name><name><surname>Macarayan</surname> <given-names>ERK</given-names></name><name><surname>Mackay</surname> <given-names>MT</given-names></name><name><surname>MacLachlan</surname> <given-names>JH</given-names></name><name><surname>Maddison</surname> <given-names>ER</given-names></name><name><surname>Madotto</surname> <given-names>F</given-names></name><name><surname>Magdy Abd El Razek</surname> <given-names>H</given-names></name><name><surname>Magdy Abd El Razek</surname> <given-names>M</given-names></name><name><surname>Maghavani</surname> <given-names>DP</given-names></name><name><surname>Majdan</surname> <given-names>M</given-names></name><name><surname>Majdzadeh</surname> <given-names>R</given-names></name><name><surname>Majeed</surname> <given-names>A</given-names></name><name><surname>Malekzadeh</surname> <given-names>R</given-names></name><name><surname>Malta</surname> <given-names>DC</given-names></name><name><surname>Manda</surname> <given-names>A-L</given-names></name><name><surname>Mandarano-Filho</surname> <given-names>LG</given-names></name><name><surname>Manguerra</surname> <given-names>H</given-names></name><name><surname>Mansournia</surname> <given-names>MA</given-names></name><name><surname>Mapoma</surname> <given-names>CC</given-names></name><name><surname>Marami</surname> <given-names>D</given-names></name><name><surname>Maravilla</surname> <given-names>JC</given-names></name><name><surname>Marcenes</surname> <given-names>W</given-names></name><name><surname>Marczak</surname> <given-names>L</given-names></name><name><surname>Marks</surname> <given-names>A</given-names></name><name><surname>Marks</surname> <given-names>GB</given-names></name><name><surname>Martinez</surname> <given-names>G</given-names></name><name><surname>Martins-Melo</surname> <given-names>FR</given-names></name><name><surname>Martopullo</surname> <given-names>I</given-names></name><name><surname>MÃ¤rz</surname> <given-names>W</given-names></name><name><surname>Marzan</surname> <given-names>MB</given-names></name><name><surname>Masci</surname> <given-names>JR</given-names></name><name><surname>Massenburg</surname> <given-names>BB</given-names></name><name><surname>Mathur</surname> <given-names>MR</given-names></name><name><surname>Mathur</surname> <given-names>P</given-names></name><name><surname>Matzopoulos</surname> <given-names>R</given-names></name><name><surname>Maulik</surname> <given-names>PK</given-names></name><name><surname>Mazidi</surname> <given-names>M</given-names></name><name><surname>McAlinden</surname> <given-names>C</given-names></name><name><surname>McGrath</surname> <given-names>JJ</given-names></name><name><surname>McKee</surname> <given-names>M</given-names></name><name><surname>McMahon</surname> <given-names>BJ</given-names></name><name><surname>Mehata</surname> <given-names>S</given-names></name><name><surname>Mehndiratta</surname> <given-names>MM</given-names></name><name><surname>Mehrotra</surname> <given-names>R</given-names></name><name><surname>Mehta</surname> <given-names>KM</given-names></name><name><surname>Mehta</surname> <given-names>V</given-names></name><name><surname>Mekonnen</surname> <given-names>TC</given-names></name><name><surname>Melese</surname> <given-names>A</given-names></name><name><surname>Melku</surname> <given-names>M</given-names></name><name><surname>Memiah</surname> <given-names>PTN</given-names></name><name><surname>Memish</surname> <given-names>ZA</given-names></name><name><surname>Mendoza</surname> <given-names>W</given-names></name><name><surname>Mengistu</surname> <given-names>DT</given-names></name><name><surname>Mengistu</surname> <given-names>G</given-names></name><name><surname>Mensah</surname> <given-names>GA</given-names></name><name><surname>Mereta</surname> <given-names>ST</given-names></name><name><surname>Meretoja</surname> <given-names>A</given-names></name><name><surname>Meretoja</surname> <given-names>TJ</given-names></name><name><surname>Mestrovic</surname> <given-names>T</given-names></name><name><surname>Mezgebe</surname> <given-names>HB</given-names></name><name><surname>Miazgowski</surname> <given-names>B</given-names></name><name><surname>Miazgowski</surname> <given-names>T</given-names></name><name><surname>Millear</surname> <given-names>AI</given-names></name><name><surname>Miller</surname> <given-names>TR</given-names></name><name><surname>Miller-Petrie</surname> <given-names>MK</given-names></name><name><surname>Mini</surname> <given-names>GK</given-names></name><name><surname>Mirabi</surname> <given-names>P</given-names></name><name><surname>Mirarefin</surname> <given-names>M</given-names></name><name><surname>Mirica</surname> <given-names>A</given-names></name><name><surname>Mirrakhimov</surname> <given-names>EM</given-names></name><name><surname>Misganaw</surname> <given-names>AT</given-names></name><name><surname>Mitiku</surname> <given-names>H</given-names></name><name><surname>Moazen</surname> <given-names>B</given-names></name><name><surname>Mohammad</surname> <given-names>KA</given-names></name><name><surname>Mohammadi</surname> <given-names>M</given-names></name><name><surname>Mohammadifard</surname> <given-names>N</given-names></name><name><surname>Mohammed</surname> <given-names>MA</given-names></name><name><surname>Mohammed</surname> <given-names>S</given-names></name><name><surname>Mohan</surname> <given-names>V</given-names></name><name><surname>Mokdad</surname> <given-names>AH</given-names></name><name><surname>Molokhia</surname> <given-names>M</given-names></name><name><surname>Monasta</surname> <given-names>L</given-names></name><name><surname>Moradi</surname> <given-names>G</given-names></name><name><surname>Moradi-Lakeh</surname> <given-names>M</given-names></name><name><surname>Moradinazar</surname> <given-names>M</given-names></name><name><surname>Moraga</surname> <given-names>P</given-names></name><name><surname>Morawska</surname> <given-names>L</given-names></name><name><surname>Moreno VelÃ¡squez</surname> <given-names>I</given-names></name><name><surname>Morgado-Da-Costa</surname> <given-names>J</given-names></name><name><surname>Morrison</surname> <given-names>SD</given-names></name><name><surname>Moschos</surname> <given-names>MM</given-names></name><name><surname>Mouodi</surname> <given-names>S</given-names></name><name><surname>Mousavi</surname> <given-names>SM</given-names></name><name><surname>Muchie</surname> <given-names>KF</given-names></name><name><surname>Mueller</surname> <given-names>UO</given-names></name><name><surname>Mukhopadhyay</surname> <given-names>S</given-names></name><name><surname>Muller</surname> <given-names>K</given-names></name><name><surname>Mumford</surname> <given-names>JE</given-names></name><name><surname>Musa</surname> <given-names>J</given-names></name><name><surname>Musa</surname> <given-names>KI</given-names></name><name><surname>Mustafa</surname> <given-names>G</given-names></name><name><surname>Muthupandian</surname> <given-names>S</given-names></name><name><surname>Nachega</surname> <given-names>JB</given-names></name><name><surname>Nagel</surname> <given-names>G</given-names></name><name><surname>Naheed</surname> <given-names>A</given-names></name><name><surname>Nahvijou</surname> <given-names>A</given-names></name><name><surname>Naik</surname> <given-names>G</given-names></name><name><surname>Nair</surname> <given-names>S</given-names></name><name><surname>Najafi</surname> <given-names>F</given-names></name><name><surname>Naldi</surname> <given-names>L</given-names></name><name><surname>Nam</surname> <given-names>HS</given-names></name><name><surname>Nangia</surname> <given-names>V</given-names></name><name><surname>Nansseu</surname> <given-names>JR</given-names></name><name><surname>Nascimento</surname> <given-names>BR</given-names></name><name><surname>Natarajan</surname> <given-names>G</given-names></name><name><surname>Neamati</surname> <given-names>N</given-names></name><name><surname>Negoi</surname> <given-names>I</given-names></name><name><surname>Negoi</surname> <given-names>RI</given-names></name><name><surname>Neupane</surname> <given-names>S</given-names></name><name><surname>Newton</surname> <given-names>CRJ</given-names></name><name><surname>Ngalesoni</surname> <given-names>FN</given-names></name><name><surname>Ngunjiri</surname> <given-names>JW</given-names></name><name><surname>Nguyen</surname> <given-names>AQ</given-names></name><name><surname>Nguyen</surname> <given-names>G</given-names></name><name><surname>Nguyen</surname> <given-names>HT</given-names></name><name><surname>Nguyen</surname> <given-names>HT</given-names></name><name><surname>Nguyen</surname> <given-names>LH</given-names></name><name><surname>Nguyen</surname> <given-names>M</given-names></name><name><surname>Nguyen</surname> <given-names>TH</given-names></name><name><surname>Nichols</surname> <given-names>E</given-names></name><name><surname>Ningrum</surname> <given-names>DNA</given-names></name><name><surname>Nirayo</surname> <given-names>YL</given-names></name><name><surname>Nixon</surname> <given-names>MR</given-names></name><name><surname>Nolutshungu</surname> <given-names>N</given-names></name><name><surname>Nomura</surname> <given-names>S</given-names></name><name><surname>Norheim</surname> <given-names>OF</given-names></name><name><surname>Noroozi</surname> <given-names>M</given-names></name><name><surname>Norrving</surname> <given-names>B</given-names></name><name><surname>Noubiap</surname> <given-names>JJ</given-names></name><name><surname>Nouri</surname> <given-names>HR</given-names></name><name><surname>Nourollahpour Shiadeh</surname> <given-names>M</given-names></name><name><surname>Nowroozi</surname> <given-names>MR</given-names></name><name><surname>Nyasulu</surname> <given-names>PS</given-names></name><name><surname>Odell</surname> <given-names>CM</given-names></name><name><surname>Ofori-Asenso</surname> <given-names>R</given-names></name><name><surname>Ogbo</surname> <given-names>FA</given-names></name><name><surname>Oh</surname> <given-names>I-H</given-names></name><name><surname>Oladimeji</surname> <given-names>O</given-names></name><name><surname>Olagunju</surname> <given-names>AT</given-names></name><name><surname>Olivares</surname> <given-names>PR</given-names></name><name><surname>Olsen</surname> <given-names>HE</given-names></name><name><surname>Olusanya</surname> <given-names>BO</given-names></name><name><surname>Olusanya</surname> <given-names>JO</given-names></name><name><surname>Ong</surname> <given-names>KL</given-names></name><name><surname>Ong</surname> <given-names>SKS</given-names></name><name><surname>Oren</surname> <given-names>E</given-names></name><name><surname>Orpana</surname> <given-names>HM</given-names></name><name><surname>Ortiz</surname> <given-names>A</given-names></name><name><surname>Ortiz</surname> <given-names>JR</given-names></name><name><surname>Otstavnov</surname> <given-names>SS</given-names></name><name><surname>Ãverland</surname> <given-names>S</given-names></name><name><surname>Owolabi</surname> <given-names>MO</given-names></name><name><surname>Ãzdemir</surname> <given-names>R</given-names></name><name><surname>P A</surname> <given-names>M</given-names></name><name><surname>Pacella</surname> <given-names>R</given-names></name><name><surname>Pakhale</surname> <given-names>S</given-names></name><name><surname>Pakhare</surname> <given-names>AP</given-names></name><name><surname>Pakpour</surname> <given-names>AH</given-names></name><name><surname>Pana</surname> <given-names>A</given-names></name><name><surname>Panda-Jonas</surname> <given-names>S</given-names></name><name><surname>Pandian</surname> <given-names>JD</given-names></name><name><surname>Parisi</surname> <given-names>A</given-names></name><name><surname>Park</surname> <given-names>E-K</given-names></name><name><surname>Parry</surname> <given-names>CDH</given-names></name><name><surname>Parsian</surname> <given-names>H</given-names></name><name><surname>Patel</surname> <given-names>S</given-names></name><name><surname>Pati</surname> <given-names>S</given-names></name><name><surname>Patton</surname> <given-names>GC</given-names></name><name><surname>Paturi</surname> <given-names>VR</given-names></name><name><surname>Paulson</surname> <given-names>KR</given-names></name><name><surname>Pereira</surname> <given-names>A</given-names></name><name><surname>Pereira</surname> <given-names>DM</given-names></name><name><surname>Perico</surname> <given-names>N</given-names></name><name><surname>Pesudovs</surname> <given-names>K</given-names></name><name><surname>Petzold</surname> <given-names>M</given-names></name><name><surname>Phillips</surname> <given-names>MR</given-names></name><name><surname>Piel</surname> <given-names>FB</given-names></name><name><surname>Pigott</surname> <given-names>DM</given-names></name><name><surname>Pillay</surname> <given-names>JD</given-names></name><name><surname>Pirsaheb</surname> <given-names>M</given-names></name><name><surname>Pishgar</surname> <given-names>F</given-names></name><name><surname>Polinder</surname> <given-names>S</given-names></name><name><surname>Postma</surname> <given-names>MJ</given-names></name><name><surname>Pourshams</surname> <given-names>A</given-names></name><name><surname>Poustchi</surname> <given-names>H</given-names></name><name><surname>Pujar</surname> <given-names>A</given-names></name><name><surname>Prakash</surname> <given-names>S</given-names></name><name><surname>Prasad</surname> <given-names>N</given-names></name><name><surname>Purcell</surname> <given-names>CA</given-names></name><name><surname>Qorbani</surname> <given-names>M</given-names></name><name><surname>Quintana</surname> <given-names>H</given-names></name><name><surname>Quistberg</surname> <given-names>DA</given-names></name><name><surname>Rade</surname> <given-names>KW</given-names></name><name><surname>Radfar</surname> <given-names>A</given-names></name><name><surname>Rafay</surname> <given-names>A</given-names></name><name><surname>Rafiei</surname> <given-names>A</given-names></name><name><surname>Rahim</surname> <given-names>F</given-names></name><name><surname>Rahimi</surname> <given-names>K</given-names></name><name><surname>Rahimi-Movaghar</surname> <given-names>A</given-names></name><name><surname>Rahman</surname> <given-names>M</given-names></name><name><surname>Rahman</surname> <given-names>MHU</given-names></name><name><surname>Rahman</surname> <given-names>MA</given-names></name><name><surname>Rai</surname> <given-names>RK</given-names></name><name><surname>Rajsic</surname> <given-names>S</given-names></name><name><surname>Ram</surname> <given-names>U</given-names></name><name><surname>Ranabhat</surname> <given-names>CL</given-names></name><name><surname>Ranjan</surname> <given-names>P</given-names></name><name><surname>Rao</surname> <given-names>PC</given-names></name><name><surname>Rawaf</surname> <given-names>DL</given-names></name><name><surname>Rawaf</surname> <given-names>S</given-names></name><name><surname>Razo-GarcÃ­a</surname> <given-names>C</given-names></name><name><surname>Reddy</surname> <given-names>KS</given-names></name><name><surname>Reiner</surname> <given-names>RC</given-names></name><name><surname>Reitsma</surname> <given-names>MB</given-names></name><name><surname>Remuzzi</surname> <given-names>G</given-names></name><name><surname>Renzaho</surname> <given-names>AMN</given-names></name><name><surname>Resnikoff</surname> <given-names>S</given-names></name><name><surname>Rezaei</surname> <given-names>S</given-names></name><name><surname>Rezaeian</surname> <given-names>S</given-names></name><name><surname>Rezai</surname> <given-names>MS</given-names></name><name><surname>Riahi</surname> <given-names>SM</given-names></name><name><surname>Ribeiro</surname> <given-names>ALP</given-names></name><name><surname>Rios-Blancas</surname> <given-names>MJ</given-names></name><name><surname>Roba</surname> <given-names>KT</given-names></name><name><surname>Roberts</surname> <given-names>NLS</given-names></name><name><surname>Robinson</surname> <given-names>SR</given-names></name><name><surname>Roever</surname> <given-names>L</given-names></name><name><surname>Ronfani</surname> <given-names>L</given-names></name><name><surname>Roshandel</surname> <given-names>G</given-names></name><name><surname>Rostami</surname> <given-names>A</given-names></name><name><surname>Rothenbacher</surname> <given-names>D</given-names></name><name><surname>Roy</surname> <given-names>A</given-names></name><name><surname>Rubagotti</surname> <given-names>E</given-names></name><name><surname>Sachdev</surname> <given-names>PS</given-names></name><name><surname>Saddik</surname> <given-names>B</given-names></name><name><surname>Sadeghi</surname> <given-names>E</given-names></name><name><surname>Safari</surname> <given-names>H</given-names></name><name><surname>Safdarian</surname> <given-names>M</given-names></name><name><surname>Safi</surname> <given-names>S</given-names></name><name><surname>Safiri</surname> <given-names>S</given-names></name><name><surname>Sagar</surname> <given-names>R</given-names></name><name><surname>Sahebkar</surname> <given-names>A</given-names></name><name><surname>Sahraian</surname> <given-names>MA</given-names></name><name><surname>Salam</surname> <given-names>N</given-names></name><name><surname>Salama</surname> <given-names>JS</given-names></name><name><surname>Salamati</surname> <given-names>P</given-names></name><name><surname>Saldanha</surname> <given-names>RDF</given-names></name><name><surname>Saleem</surname> <given-names>Z</given-names></name><name><surname>Salimi</surname> <given-names>Y</given-names></name><name><surname>Salvi</surname> <given-names>SS</given-names></name><name><surname>Salz</surname> <given-names>I</given-names></name><name><surname>Sambala</surname> <given-names>EZ</given-names></name><name><surname>Samy</surname> <given-names>AM</given-names></name><name><surname>Sanabria</surname> <given-names>J</given-names></name><name><surname>Sanchez-NiÃ±o</surname> <given-names>MD</given-names></name><name><surname>Santomauro</surname> <given-names>DF</given-names></name><name><surname>Santos</surname> <given-names>IS</given-names></name><name><surname>Santos</surname> <given-names>JV</given-names></name><name><surname>Milicevic</surname> <given-names>MMS</given-names></name><name><surname>Sao Jose</surname> <given-names>BP</given-names></name><name><surname>Sarker</surname> <given-names>AR</given-names></name><name><surname>Sarmiento-SuÃ¡rez</surname> <given-names>R</given-names></name><name><surname>Sarrafzadegan</surname> <given-names>N</given-names></name><name><surname>Sartorius</surname> <given-names>B</given-names></name><name><surname>Sarvi</surname> <given-names>S</given-names></name><name><surname>Sathian</surname> <given-names>B</given-names></name><name><surname>Satpathy</surname> <given-names>M</given-names></name><name><surname>Sawant</surname> <given-names>AR</given-names></name><name><surname>Sawhney</surname> <given-names>M</given-names></name><name><surname>Saxena</surname> <given-names>S</given-names></name><name><surname>Sayyah</surname> <given-names>M</given-names></name><name><surname>Schaeffner</surname> <given-names>E</given-names></name><name><surname>Schmidt</surname> <given-names>MI</given-names></name><name><surname>Schneider</surname> <given-names>IJC</given-names></name><name><surname>SchÃ¶ttker</surname> <given-names>B</given-names></name><name><surname>Schutte</surname> <given-names>AE</given-names></name><name><surname>Schwebel</surname> <given-names>DC</given-names></name><name><surname>Schwendicke</surname> <given-names>F</given-names></name><name><surname>Scott</surname> <given-names>JG</given-names></name><name><surname>Sekerija</surname> <given-names>M</given-names></name><name><surname>Sepanlou</surname> <given-names>SG</given-names></name><name><surname>ServÃ¡n-Mori</surname> <given-names>E</given-names></name><name><surname>Seyedmousavi</surname> <given-names>S</given-names></name><name><surname>Shabaninejad</surname> <given-names>H</given-names></name><name><surname>Shackelford</surname> <given-names>KA</given-names></name><name><surname>Shafieesabet</surname> <given-names>A</given-names></name><name><surname>Shahbazi</surname> <given-names>M</given-names></name><name><surname>Shaheen</surname> <given-names>AA</given-names></name><name><surname>Shaikh</surname> <given-names>MA</given-names></name><name><surname>Shams-Beyranvand</surname> <given-names>M</given-names></name><name><surname>Shamsi</surname> <given-names>M</given-names></name><name><surname>Shamsizadeh</surname> <given-names>M</given-names></name><name><surname>Sharafi</surname> <given-names>K</given-names></name><name><surname>Sharif</surname> <given-names>M</given-names></name><name><surname>Sharif-Alhoseini</surname> <given-names>M</given-names></name><name><surname>Sharma</surname> <given-names>R</given-names></name><name><surname>She</surname> <given-names>J</given-names></name><name><surname>Sheikh</surname> <given-names>A</given-names></name><name><surname>Shi</surname> <given-names>P</given-names></name><name><surname>Shiferaw</surname> <given-names>MS</given-names></name><name><surname>Shigematsu</surname> <given-names>M</given-names></name><name><surname>Shiri</surname> <given-names>R</given-names></name><name><surname>Shirkoohi</surname> <given-names>R</given-names></name><name><surname>Shiue</surname> <given-names>I</given-names></name><name><surname>Shokraneh</surname> <given-names>F</given-names></name><name><surname>Shrime</surname> <given-names>MG</given-names></name><name><surname>Si</surname> <given-names>S</given-names></name><name><surname>Siabani</surname> <given-names>S</given-names></name><name><surname>Siddiqi</surname> <given-names>TJ</given-names></name><name><surname>Sigfusdottir</surname> <given-names>ID</given-names></name><name><surname>Sigurvinsdottir</surname> <given-names>R</given-names></name><name><surname>Silberberg</surname> <given-names>DH</given-names></name><name><surname>Silva</surname> <given-names>DAS</given-names></name><name><surname>Silva</surname> <given-names>JP</given-names></name><name><surname>Silva</surname> <given-names>NTD</given-names></name><name><surname>Silveira</surname> <given-names>DGA</given-names></name><name><surname>Singh</surname> <given-names>JA</given-names></name><name><surname>Singh</surname> <given-names>NP</given-names></name><name><surname>Singh</surname> <given-names>PK</given-names></name><name><surname>Singh</surname> <given-names>V</given-names></name><name><surname>Sinha</surname> <given-names>DN</given-names></name><name><surname>Sliwa</surname> <given-names>K</given-names></name><name><surname>Smith</surname> <given-names>M</given-names></name><name><surname>Sobaih</surname> <given-names>BH</given-names></name><name><surname>Sobhani</surname> <given-names>S</given-names></name><name><surname>Sobngwi</surname> <given-names>E</given-names></name><name><surname>Soneji</surname> <given-names>SS</given-names></name><name><surname>Soofi</surname> <given-names>M</given-names></name><name><surname>Sorensen</surname> <given-names>RJD</given-names></name><name><surname>Soriano</surname> <given-names>JB</given-names></name><name><surname>Soyiri</surname> <given-names>IN</given-names></name><name><surname>Sposato</surname> <given-names>LA</given-names></name><name><surname>Sreeramareddy</surname> <given-names>CT</given-names></name><name><surname>Srinivasan</surname> <given-names>V</given-names></name><name><surname>Stanaway</surname> <given-names>JD</given-names></name><name><surname>Starodubov</surname> <given-names>VI</given-names></name><name><surname>Stathopoulou</surname> <given-names>V</given-names></name><name><surname>Stein</surname> <given-names>DJ</given-names></name><name><surname>Steiner</surname> <given-names>C</given-names></name><name><surname>Stewart</surname> <given-names>LG</given-names></name><name><surname>Stokes</surname> <given-names>MA</given-names></name><name><surname>Subart</surname> <given-names>ML</given-names></name><name><surname>Sudaryanto</surname> <given-names>A</given-names></name><name><surname>Sufiyan</surname> <given-names>MB</given-names></name><name><surname>Sur</surname> <given-names>PJ</given-names></name><name><surname>Sutradhar</surname> <given-names>I</given-names></name><name><surname>Sykes</surname> <given-names>BL</given-names></name><name><surname>Sylaja</surname> <given-names>PN</given-names></name><name><surname>Sylte</surname> <given-names>DO</given-names></name><name><surname>Szoeke</surname> <given-names>CEI</given-names></name><name><surname>TabarÃ©s-Seisdedos</surname> <given-names>R</given-names></name><name><surname>Tabuchi</surname> <given-names>T</given-names></name><name><surname>Tadakamadla</surname> <given-names>SK</given-names></name><name><surname>Takahashi</surname> <given-names>K</given-names></name><name><surname>Tandon</surname> <given-names>N</given-names></name><name><surname>Tassew</surname> <given-names>SG</given-names></name><name><surname>Taveira</surname> <given-names>N</given-names></name><name><surname>Tehrani-Banihashemi</surname> <given-names>A</given-names></name><name><surname>Tekalign</surname> <given-names>TG</given-names></name><name><surname>Tekle</surname> <given-names>MG</given-names></name><name><surname>Temsah</surname> <given-names>M-H</given-names></name><name><surname>Temsah</surname> <given-names>O</given-names></name><name><surname>Terkawi</surname> <given-names>AS</given-names></name><name><surname>Teshale</surname> <given-names>MY</given-names></name><name><surname>Tessema</surname> <given-names>B</given-names></name><name><surname>Tessema</surname> <given-names>GA</given-names></name><name><surname>Thankappan</surname> <given-names>KR</given-names></name><name><surname>Thirunavukkarasu</surname> <given-names>S</given-names></name><name><surname>Thomas</surname> <given-names>N</given-names></name><name><surname>Thrift</surname> <given-names>AG</given-names></name><name><surname>Thurston</surname> <given-names>GD</given-names></name><name><surname>Tilahun</surname> <given-names>B</given-names></name><name><surname>To</surname> <given-names>QG</given-names></name><name><surname>Tobe-Gai</surname> <given-names>R</given-names></name><name><surname>Tonelli</surname> <given-names>M</given-names></name><name><surname>Topor-Madry</surname> <given-names>R</given-names></name><name><surname>Torre</surname> <given-names>AE</given-names></name><name><surname>Tortajada-GirbÃ©s</surname> <given-names>M</given-names></name><name><surname>Touvier</surname> <given-names>M</given-names></name><name><surname>Tovani-Palone</surname> <given-names>MR</given-names></name><name><surname>Tran</surname> <given-names>BX</given-names></name><name><surname>Tran</surname> <given-names>KB</given-names></name><name><surname>Tripathi</surname> <given-names>S</given-names></name><name><surname>Troeger</surname> <given-names>CE</given-names></name><name><surname>Truelsen</surname> <given-names>TC</given-names></name><name><surname>Truong</surname> <given-names>NT</given-names></name><name><surname>Tsadik</surname> <given-names>AG</given-names></name><name><surname>Tsoi</surname> <given-names>D</given-names></name><name><surname>Tudor Car</surname> <given-names>L</given-names></name><name><surname>Tuzcu</surname> <given-names>EM</given-names></name><name><surname>Tyrovolas</surname> <given-names>S</given-names></name><name><surname>Ukwaja</surname> <given-names>KN</given-names></name><name><surname>Ullah</surname> <given-names>I</given-names></name><name><surname>Undurraga</surname> <given-names>EA</given-names></name><name><surname>Updike</surname> <given-names>RL</given-names></name><name><surname>Usman</surname> <given-names>MS</given-names></name><name><surname>Uthman</surname> <given-names>OA</given-names></name><name><surname>Uzun</surname> <given-names>SB</given-names></name><name><surname>Vaduganathan</surname> <given-names>M</given-names></name><name><surname>Vaezi</surname> <given-names>A</given-names></name><name><surname>Vaidya</surname> <given-names>G</given-names></name><name><surname>Valdez</surname> <given-names>PR</given-names></name><name><surname>Varavikova</surname> <given-names>E</given-names></name><name><surname>Vasankari</surname> <given-names>TJ</given-names></name><name><surname>Venketasubramanian</surname> <given-names>N</given-names></name><name><surname>Villafaina</surname> <given-names>S</given-names></name><name><surname>Violante</surname> <given-names>FS</given-names></name><name><surname>Vladimirov</surname> <given-names>SK</given-names></name><name><surname>Vlassov</surname> <given-names>V</given-names></name><name><surname>Vollset</surname> <given-names>SE</given-names></name><name><surname>Vos</surname> <given-names>T</given-names></name><name><surname>Wagner</surname> <given-names>GR</given-names></name><name><surname>Wagnew</surname> <given-names>FS</given-names></name><name><surname>Waheed</surname> <given-names>Y</given-names></name><name><surname>Wallin</surname> <given-names>MT</given-names></name><name><surname>Walson</surname> <given-names>JL</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>Y-P</given-names></name><name><surname>Wassie</surname> <given-names>MM</given-names></name><name><surname>Weiderpass</surname> <given-names>E</given-names></name><name><surname>Weintraub</surname> <given-names>RG</given-names></name><name><surname>Weldegebreal</surname> <given-names>F</given-names></name><name><surname>Weldegwergs</surname> <given-names>KG</given-names></name><name><surname>Werdecker</surname> <given-names>A</given-names></name><name><surname>Werkneh</surname> <given-names>AA</given-names></name><name><surname>West</surname> <given-names>TE</given-names></name><name><surname>Westerman</surname> <given-names>R</given-names></name><name><surname>Whiteford</surname> <given-names>HA</given-names></name><name><surname>Widecka</surname> <given-names>J</given-names></name><name><surname>Wilner</surname> <given-names>LB</given-names></name><name><surname>Wilson</surname> <given-names>S</given-names></name><name><surname>Winkler</surname> <given-names>AS</given-names></name><name><surname>Wiysonge</surname> <given-names>CS</given-names></name><name><surname>Wolfe</surname> <given-names>CDA</given-names></name><name><surname>Wu</surname> <given-names>S</given-names></name><name><surname>Wu</surname> <given-names>Y-C</given-names></name><name><surname>Wyper</surname> <given-names>GMA</given-names></name><name><surname>Xavier</surname> <given-names>D</given-names></name><name><surname>Xu</surname> <given-names>G</given-names></name><name><surname>Yadgir</surname> <given-names>S</given-names></name><name><surname>Yadollahpour</surname> <given-names>A</given-names></name><name><surname>Yahyazadeh Jabbari</surname> <given-names>SH</given-names></name><name><surname>Yakob</surname> <given-names>B</given-names></name><name><surname>Yan</surname> <given-names>LL</given-names></name><name><surname>Yano</surname> <given-names>Y</given-names></name><name><surname>Yaseri</surname> <given-names>M</given-names></name><name><surname>Yasin</surname> <given-names>YJ</given-names></name><name><surname>YentÃ¼r</surname> <given-names>GK</given-names></name><name><surname>Yeshaneh</surname> <given-names>A</given-names></name><name><surname>Yimer</surname> <given-names>EM</given-names></name><name><surname>Yip</surname> <given-names>P</given-names></name><name><surname>Yirsaw</surname> <given-names>BD</given-names></name><name><surname>Yisma</surname> <given-names>E</given-names></name><name><surname>Yonemoto</surname> <given-names>N</given-names></name><name><surname>Yonga</surname> <given-names>G</given-names></name><name><surname>Yoon</surname> <given-names>S-J</given-names></name><name><surname>Yotebieng</surname> <given-names>M</given-names></name><name><surname>Younis</surname> <given-names>MZ</given-names></name><name><surname>Yousefifard</surname> <given-names>M</given-names></name><name><surname>Yu</surname> <given-names>C</given-names></name><name><surname>Zadnik</surname> <given-names>V</given-names></name><name><surname>Zaidi</surname> <given-names>Z</given-names></name><name><surname>Zaman</surname> <given-names>SB</given-names></name><name><surname>Zamani</surname> <given-names>M</given-names></name><name><surname>Zare</surname> <given-names>Z</given-names></name><name><surname>Zeleke</surname> <given-names>AJ</given-names></name><name><surname>Zenebe</surname> <given-names>ZM</given-names></name><name><surname>Zhang</surname> <given-names>AL</given-names></name><name><surname>Zhang</surname> <given-names>K</given-names></name><name><surname>Zhou</surname> <given-names>M</given-names></name><name><surname>Zodpey</surname> <given-names>S</given-names></name><name><surname>Zuhlke</surname> <given-names>LJ</given-names></name><name><surname>Naghavi</surname> <given-names>M</given-names></name><name><surname>Murray</surname> <given-names>CJL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980â2017: a systematic analysis for the Global Burden of Disease Study 2017</article-title><source>The Lancet</source><volume>392</volume><fpage>1736</fpage><lpage>1788</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)32203-7</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaima</surname> <given-names>C</given-names></name><name><surname>Moorthi</surname> <given-names>P</given-names></name><name><surname>Shaheen</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cardiovascular diseases: traditional and non-traditional risk factors</article-title><source>Journal of Medical and Allied Sciences</source><volume>6</volume><elocation-id>46</elocation-id><pub-id pub-id-type="doi">10.5455/jmas.228597</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sirtori</surname> <given-names>CR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The pharmacology of statins</article-title><source>Pharmacological Research</source><volume>88</volume><fpage>3</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2014.03.002</pub-id><pub-id pub-id-type="pmid">24657242</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soininen</surname> <given-names>P</given-names></name><name><surname>Kangas</surname> <given-names>AJ</given-names></name><name><surname>WÃ¼rtz</surname> <given-names>P</given-names></name><name><surname>Suna</surname> <given-names>T</given-names></name><name><surname>Ala-Korpela</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics</article-title><source>Circulation. Cardiovascular Genetics</source><volume>8</volume><fpage>192</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1161/CIRCGENETICS.114.000216</pub-id><pub-id pub-id-type="pmid">25691689</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valeri</surname> <given-names>L</given-names></name><name><surname>VanderWeele</surname> <given-names>TJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mediation analysis allowing for exposureâmediator interactions and causal interpretation: Theoretical assumptions and implementation with SAS and SPSS macros</article-title><source>Psychological Methods</source><volume>18</volume><fpage>137</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1037/a0031034</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varbo</surname> <given-names>A</given-names></name><name><surname>Benn</surname> <given-names>M</given-names></name><name><surname>TybjÃ¦rg-Hansen</surname> <given-names>A</given-names></name><name><surname>JÃ¸rgensen</surname> <given-names>AB</given-names></name><name><surname>Frikke-Schmidt</surname> <given-names>R</given-names></name><name><surname>Nordestgaard</surname> <given-names>BG</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Remnant cholesterol as a causal risk factor for ischemic heart disease</article-title><source>Journal of the American College of Cardiology</source><volume>61</volume><fpage>427</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2012.08.1026</pub-id><pub-id pub-id-type="pmid">23265341</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>WÃ¼rtz</surname> <given-names>P</given-names></name><name><surname>Wang</surname> <given-names>Q</given-names></name><name><surname>Kangas</surname> <given-names>AJ</given-names></name><name><surname>Richmond</surname> <given-names>RC</given-names></name><name><surname>Skarp</surname> <given-names>J</given-names></name><name><surname>Tiainen</surname> <given-names>M</given-names></name><name><surname>Tynkkynen</surname> <given-names>T</given-names></name><name><surname>Soininen</surname> <given-names>P</given-names></name><name><surname>Havulinna</surname> <given-names>AS</given-names></name><name><surname>Kaakinen</surname> <given-names>M</given-names></name><name><surname>Viikari</surname> <given-names>JS</given-names></name><name><surname>Savolainen</surname> <given-names>MJ</given-names></name><name><surname>KÃ¤hÃ¶nen</surname> <given-names>M</given-names></name><name><surname>LehtimÃ¤ki</surname> <given-names>T</given-names></name><name><surname>MÃ¤nnistÃ¶</surname> <given-names>S</given-names></name><name><surname>Blankenberg</surname> <given-names>S</given-names></name><name><surname>Zeller</surname> <given-names>T</given-names></name><name><surname>Laitinen</surname> <given-names>J</given-names></name><name><surname>Pouta</surname> <given-names>A</given-names></name><name><surname>MÃ¤ntyselkÃ¤</surname> <given-names>P</given-names></name><name><surname>Vanhala</surname> <given-names>M</given-names></name><name><surname>Elliott</surname> <given-names>P</given-names></name><name><surname>PietilÃ¤inen</surname> <given-names>KH</given-names></name><name><surname>Ripatti</surname> <given-names>S</given-names></name><name><surname>Salomaa</surname> <given-names>V</given-names></name><name><surname>Raitakari</surname> <given-names>OT</given-names></name><name><surname>JÃ¤rvelin</surname> <given-names>MR</given-names></name><name><surname>Smith</surname> <given-names>GD</given-names></name><name><surname>Ala-Korpela</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Metabolic signatures of adiposity in young adults: mendelian randomization analysis and effects of weight change</article-title><source>PLOS Medicine</source><volume>11</volume><elocation-id>e1001765</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pmed.1001765</pub-id><pub-id pub-id-type="pmid">25490400</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>WÃ¼rtz</surname> <given-names>P</given-names></name><name><surname>Havulinna</surname> <given-names>AS</given-names></name><name><surname>Soininen</surname> <given-names>P</given-names></name><name><surname>Tynkkynen</surname> <given-names>T</given-names></name><name><surname>Prieto-Merino</surname> <given-names>D</given-names></name><name><surname>Tillin</surname> <given-names>T</given-names></name><name><surname>Ghorbani</surname> <given-names>A</given-names></name><name><surname>Artati</surname> <given-names>A</given-names></name><name><surname>Wang</surname> <given-names>Q</given-names></name><name><surname>Tiainen</surname> <given-names>M</given-names></name><name><surname>Kangas</surname> <given-names>AJ</given-names></name><name><surname>Kettunen</surname> <given-names>J</given-names></name><name><surname>Kaikkonen</surname> <given-names>J</given-names></name><name><surname>MikkilÃ¤</surname> <given-names>V</given-names></name><name><surname>Jula</surname> <given-names>A</given-names></name><name><surname>KÃ¤hÃ¶nen</surname> <given-names>M</given-names></name><name><surname>LehtimÃ¤ki</surname> <given-names>T</given-names></name><name><surname>Lawlor</surname> <given-names>DA</given-names></name><name><surname>Gaunt</surname> <given-names>TR</given-names></name><name><surname>Hughes</surname> <given-names>AD</given-names></name><name><surname>Sattar</surname> <given-names>N</given-names></name><name><surname>Illig</surname> <given-names>T</given-names></name><name><surname>Adamski</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>TJ</given-names></name><name><surname>Perola</surname> <given-names>M</given-names></name><name><surname>Ripatti</surname> <given-names>S</given-names></name><name><surname>Vasan</surname> <given-names>RS</given-names></name><name><surname>Raitakari</surname> <given-names>OT</given-names></name><name><surname>Gerszten</surname> <given-names>RE</given-names></name><name><surname>Casas</surname> <given-names>JP</given-names></name><name><surname>Chaturvedi</surname> <given-names>N</given-names></name><name><surname>Ala-Korpela</surname> <given-names>M</given-names></name><name><surname>Salomaa</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts</article-title><source>Circulation</source><volume>131</volume><fpage>774</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.114.013116</pub-id><pub-id pub-id-type="pmid">25573147</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>WÃ¼rtz</surname> <given-names>P</given-names></name><name><surname>Cook</surname> <given-names>S</given-names></name><name><surname>Wang</surname> <given-names>Q</given-names></name><name><surname>Tiainen</surname> <given-names>M</given-names></name><name><surname>Tynkkynen</surname> <given-names>T</given-names></name><name><surname>Kangas</surname> <given-names>AJ</given-names></name><name><surname>Soininen</surname> <given-names>P</given-names></name><name><surname>Laitinen</surname> <given-names>J</given-names></name><name><surname>Viikari</surname> <given-names>J</given-names></name><name><surname>KÃ¤hÃ¶nen</surname> <given-names>M</given-names></name><name><surname>LehtimÃ¤ki</surname> <given-names>T</given-names></name><name><surname>Perola</surname> <given-names>M</given-names></name><name><surname>Blankenberg</surname> <given-names>S</given-names></name><name><surname>Zeller</surname> <given-names>T</given-names></name><name><surname>MÃ¤nnistÃ¶</surname> <given-names>S</given-names></name><name><surname>Salomaa</surname> <given-names>V</given-names></name><name><surname>JÃ¤rvelin</surname> <given-names>MR</given-names></name><name><surname>Raitakari</surname> <given-names>OT</given-names></name><name><surname>Ala-Korpela</surname> <given-names>M</given-names></name><name><surname>Leon</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2016">2016a</year><article-title>Metabolic profiling of alcohol consumption in 9778 young adults</article-title><source>International Journal of Epidemiology</source><volume>45</volume><fpage>1493</fpage><lpage>1506</lpage><pub-id pub-id-type="doi">10.1093/ije/dyw175</pub-id><pub-id pub-id-type="pmid">27494945</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>WÃ¼rtz</surname> <given-names>P</given-names></name><name><surname>Wang</surname> <given-names>Q</given-names></name><name><surname>Soininen</surname> <given-names>P</given-names></name><name><surname>Kangas</surname> <given-names>AJ</given-names></name><name><surname>Fatemifar</surname> <given-names>G</given-names></name><name><surname>Tynkkynen</surname> <given-names>T</given-names></name><name><surname>Tiainen</surname> <given-names>M</given-names></name><name><surname>Perola</surname> <given-names>M</given-names></name><name><surname>Tillin</surname> <given-names>T</given-names></name><name><surname>Hughes</surname> <given-names>AD</given-names></name><name><surname>MÃ¤ntyselkÃ¤</surname> <given-names>P</given-names></name><name><surname>KÃ¤hÃ¶nen</surname> <given-names>M</given-names></name><name><surname>LehtimÃ¤ki</surname> <given-names>T</given-names></name><name><surname>Sattar</surname> <given-names>N</given-names></name><name><surname>Hingorani</surname> <given-names>AD</given-names></name><name><surname>Casas</surname> <given-names>JP</given-names></name><name><surname>Salomaa</surname> <given-names>V</given-names></name><name><surname>KivimÃ¤ki</surname> <given-names>M</given-names></name><name><surname>JÃ¤rvelin</surname> <given-names>MR</given-names></name><name><surname>Davey Smith</surname> <given-names>G</given-names></name><name><surname>Vanhala</surname> <given-names>M</given-names></name><name><surname>Lawlor</surname> <given-names>DA</given-names></name><name><surname>Raitakari</surname> <given-names>OT</given-names></name><name><surname>Chaturvedi</surname> <given-names>N</given-names></name><name><surname>Kettunen</surname> <given-names>J</given-names></name><name><surname>Ala-Korpela</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016b</year><article-title>Metabolomic profiling of statin use and genetic inhibition of HMG-CoA reductase</article-title><source>Journal of the American College of Cardiology</source><volume>67</volume><fpage>1200</fpage><lpage>1210</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2015.12.060</pub-id><pub-id pub-id-type="pmid">26965542</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>YX</given-names></name><name><surname>Wang</surname> <given-names>XL</given-names></name><name><surname>Leong</surname> <given-names>PM</given-names></name><name><surname>Zhang</surname> <given-names>HM</given-names></name><name><surname>Yang</surname> <given-names>XG</given-names></name><name><surname>Kong</surname> <given-names>LZ</given-names></name><name><surname>Zhai</surname> <given-names>FY</given-names></name><name><surname>Cheng</surname> <given-names>YY</given-names></name><name><surname>Guo</surname> <given-names>JS</given-names></name><name><surname>Su</surname> <given-names>YX</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>New chinese dietary guidelines: healthy eating patterns and food-based dietary recommendations</article-title><source>Asia Pacific Journal of Clinical Nutrition</source><volume>27</volume><fpage>908</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.6133/apjcn.072018.03</pub-id><pub-id pub-id-type="pmid">30045438</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>N</given-names></name><name><surname>Yu</surname> <given-names>C</given-names></name><name><surname>Guo</surname> <given-names>Y</given-names></name><name><surname>Bian</surname> <given-names>Z</given-names></name><name><surname>Han</surname> <given-names>Y</given-names></name><name><surname>Yang</surname> <given-names>L</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Du</surname> <given-names>H</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Liu</surname> <given-names>F</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Chen</surname> <given-names>Z</given-names></name><name><surname>Lv</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Adherence to a healthy lifestyle and all-cause and cause-specific mortality in chinese adults: a 10-year prospective study of 0.5 million people</article-title><source>International Journal of Behavioral Nutrition and Physical Activity</source><volume>16</volume><elocation-id>98</elocation-id><pub-id pub-id-type="doi">10.1186/s12966-019-0860-z</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.60999.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Janus</surname><given-names>Edward D</given-names></name><role>Reviewing Editor</role><aff><institution>University of Melbourne</institution><country>Australia</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Janus</surname><given-names>Edward D</given-names></name><role>Reviewer</role><aff><institution>University of Melbourne</institution><country>Australia</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Giles</surname><given-names>Corey</given-names> </name><role>Reviewer</role><aff><institution/></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>The novel approach is a detailed lipidomic profile of 61 plasma metabolites by NMR at baseline in a large number of Chinese subjects associated with five individual lifestyle related factors ( dietary habit, exercise, non-smoking, adiposity and alcohol consumption) either singly or in combination and the impact of these on vascular disease after 20 years of follow up. Adherence as expected improved both the profile and outcomes.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Improved lipidomic profile mediates the effects of adherence to healthy lifestyles on coronary heart disease&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, including Edward D Janus as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Matthias Barton as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Corey Giles (Reviewer #2).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, when editors judge that a submitted work as a whole belongs in <italic>eLife</italic> but that some conclusions require a modest amount of additional new data, as they do with your paper, we are asking that the manuscript be revised to either limit claims to those supported by data in hand, or to explicitly state that the relevant conclusions require additional supporting data.</p><p>Our expectation is that the authors will eventually carry out the additional experiments and report on how they affect the relevant conclusions either in a preprint on bioRxiv or medRxiv, or if appropriate, as a Research Advance in <italic>eLife</italic>, either of which would be linked to the original paper.</p><p>Summary:</p><p>The authors report, in 4681 subjects, the detailed baseline lipidomic profile (61 plasma metabolites by NMR) associated with five individual healthy lifestyle related factors singly or in combination (dietary habit, exercise, non-smoking, adiposity and exercise) and relate these to the presence of coronary or cerebrovascular disease after approximately 20 years of follow up vs the baseline parameters for a further 1513 non affected matched control subjects. All measurements were without lipid lowering drugs.</p><p>They used regression to assess associations between health life-style factors (HLF); mediation analysis to assess mediating effects of metabolites on coronary heart disease HLF; pharmacomimetic gene scores to estimate the genetic effects of HMGCR and ACLY.</p><p>The beneficial effects of the five lifestyle characteristics are already well known so the main new data is the detailed lipidomic profile in a Chinese population and its implications. Participants who adhered to a combined healthy lifestyle were more likely to have a cardio-protective lipidomic profile which jointly mediated 14% of the protective effect of combined healthy lifestyle on CHD risk.</p><p>The manuscript is well written overall and has important clinical interpretation although there is an overload of information in the supplementary material. There are some issues of clarity in the text and some major limitations in the analysis which need to be addressed.</p><p>Revisions for this paper:</p><p>1).While the Title is clear and acceptable the statement in the Abstract â Healthy lifestyles included baseline smoking, alcohol consumption, dietary habit, physical activity, and adiposity levels â is not appropriate as some of these are unhealthy lifestyles or as in the case of adiposity are not even lifestyles. Better to use &quot;Baseline lifestyle related characteristics&quot; throughout the manuscript.</p><p>Also in the Abstract â significant mediation effects in the pathway from healthy lifestyles to CHD â is not correct as this says that healthy lifestyles cause CHD. If you delete &quot;healthy&quot; itâs then correct but even better is to leave your wording but change it to &quot;CHD reduction&quot;.</p><p>2) In the last paragraph of the Introduction say something in one or two sentences about the cohort, CHD and the controls. Without this the Results section is difficult to understand because it precedes the Materials and methods section.</p><p>3) Results</p><p>At beginning please list the five Healthy lifestyle factors.</p><p>4) Mediation effects of lipid metabolites in the association between HLFs and CHD risk. In the first line you need to make it clear what is meant by CHD risk that is state it is the presence of coronary or cerebrovascular disease in members of the cohort during the follow up period. Also CHD means coronary heart disease so cerebro-vascular disease is not CHD. You need to use Coronary heart disease AND cerebrovascular disease throughout the paper in title, text, tables, figures. You need to also make it very clear that you have included intracerebral haemorrhage because this is not atherosclerotic in origin. Ideally you would show that excluding haemorrhagic stroke while retaining ischemic stroke does not substantially change your overall findings/implications.</p><p>5) Please provide the mean and SD number of years of follow-up for the cohort and specify how reliable and complete follow up was. This is important in your analysis. If incomplete then itâs a limitation to be discussed.</p><p>6) A major limitation of this study is the dichotomization of health factors, summing the number of factors for each person, then stratifying participants into one of three groups. I appreciate the authors intention to create an aggregate score for âhealth behaviorâ, but used in this context, it is indeed a limitation.</p><p>The HLF used in this study have all been linked with CHD. Dichotomizing them results in substantial loss of information. Summing across these scores then leads to a loss in specificity for the underlying biology. In effect, you may produce a variable that associates with CHD, but does not provide any more biological insight than what we knew over 50 years ago.</p><p>As shown in the supplement, much of the HLF could be driven by adiposity alone. This is after dichotomization, so I would expect even stronger results if the authors used raw BMI or WC. Some of the individual HLF have vastly different association strengths with metabolites, some even in the opposite direction to each other. The aggregate HLF just ends up losing power in this situation and hides the underlying biology. Associations of individual HLF (without dichotomization) provides information that can help improve our understanding of the metabolic consequences of these HLF. The current manuscript is lacking this insight.</p><p>Importantly, mediation analysis is no longer valid when the exposure variable is dichotomized. Causal mediation analysis will suggest a mediation effect even when this is not true. There is no getting around this, unfortunately. Whenever information is removed from the exposure, the putative mediating variable will attempt to explain it.</p><p>7) Alcohol consumption appeared to have a complex effect on the lipoprotein profile. From Table 1, around 28.3% of the study population with &gt;= 4 healthy lifestyle factors were considered as moderate alcohol consumers. What was the general distribution of alcohol intake among study population, e.g., non-regular, previous regular, or heavy intake? This information should be given to better understand the effect of alcohol consumption.</p><p>8) The authors appear to have attempted a two-factorial analysis of gene scores by the HLF aggregate. It is now known that using the derived scores and an interaction term provides much more power for identifying independence or importance.</p><p>I am not sure why this analysis was performed: &quot;We also examined whether the association between HLFs and lipid metabolites differed by scores of HMGCR, ACLY, or their sum score&quot;. Each genetic variant often has small effect sizes (much smaller than a typical dose of statin). Even the combined score would be very small compared to this. Assuming there isn't some underlying confounding, the inheritance of the genetic variants should be randomly distributed among the population. I do not believe there is any rationale that the association of metabolites with HLF should differ under these conditions.</p><p>9) The authors use the 1000 Genomes reference panel (Phase 3) to impute variants. Is this database (relative dearth of Chinese) appropriate to use for imputing variants in a Chinese population? The authors constructed genetic sores to mimic the effect of statins and ACLY inhibitors based on the Chinese population and also the European population. Use of the genetic scores based on the European population observed similar but weaker associations, especially for some lipid metabolites (small VLDL-TG and LDL-TG) (Supplementary file 1E).</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.60999.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Revisions for this paper:</p><p>1) While the Title is clear and acceptable the statement in the Abstract â Healthy lifestyles included baseline smoking, alcohol consumption, dietary habit, physical activity, and adiposity levels â is not appropriate as some of these are unhealthy lifestyles or as in the case of adiposity are not even lifestyles. Better to use &quot;Baseline lifestyle related characteristics&quot; throughout the manuscript.</p><p>Also in the Abstract â significant mediation effects in the pathway from healthy lifestyles to CHD â is not correct as this says that healthy lifestyles cause CHD. If you delete &quot;healthy&quot; itâs then correct but even better is to leave your wording but change it to &quot;CHD reduction&quot;.</p></disp-quote><p>We thank the reviewer for pointing this out. We included adiposity measures as a lifestyle factor to assess energy balance, same as previous study (1). We have revised to use âbaseline lifestyle related characteristicsâ or change the wording of each lifestyle throughout the manuscript to keep consistent. We also added âreductionâ in the Abstract section.</p><disp-quote content-type="editor-comment"><p>2) In the last paragraph of the Introduction say something in one or two sentences about the cohort, CHD and the controls. Without this the Results section is difficult to understand because it precedes the Materials and methods section.</p></disp-quote><p>We thank the reviewer for pointing this out. We have added a brief description of the study population at the end of the Introduction section.</p><disp-quote content-type="editor-comment"><p>3) Results</p><p>At beginning please list the five Healthy lifestyle factors.</p></disp-quote><p>We have added to help better understanding.</p><disp-quote content-type="editor-comment"><p>4) Mediation effects of lipid metabolites in the association between HLFs and CHD risk. In the first line you need to make it clear what is meant by CHD risk that is state it is the presence of coronary or cerebrovascular disease in members of the cohort during the follow up period. Also CHD means coronary heart disease so cerebro-vascular disease is not CHD. You need to use Coronary heart disease AND cerebrovascular disease throughout the paper in title, text, tables, figures. You need to also make it very clear that you have included intracerebral haemorrhage because this is not atherosclerotic in origin. Ideally you would show that excluding haemorrhagic stroke while retaining ischemic stroke does not substantially change your overall findings/implications.</p></disp-quote><p>Of the total 4,681 participants, cases were those who had a newly developed fatal or nonfatal disease during follow-up: (1) CHD: fatal ischemic heart disease coded as ICD-10 I20-I25 and nonfatal myocardial infarction coded as I21-I23 (n=927); (2) ischaemic stroke: ICD-10 I63 or I69.3 (n=1,114); (3) intracerebral haemorrhage: ICD-10 I61 or I69.1 (n=1,127). Case status was defined as the disease first occurred in each participant. Common controls were selected by frequency matching to combined cases by age, sex, and study area (n=1,513).</p><p>In the analyses of HLFs and metabolites, we included all 4,681 participants and adjusted for case/control status to increase power. We also restricted analyses to control participants as a sensitivity analysis (Supplementary file 1B). In the analyses of metabolites and CHD, and corresponding mediation analyses, we excluded both ischaemic and haemorrhagic stroke. We apologize for the confusion because the Results section precedes the Materials and methods section. We have added a brief description of the study participants involved in this part of analyses in the âResult â Mediation effectsâ section and the last paragraph of the Introduction section.</p><disp-quote content-type="editor-comment"><p>5) Please provide the mean and SD number of years of follow-up for the cohort and specify how reliable and complete follow up was.This is important in your analysis. If incomplete then itâs a limitation to be discussed.</p></disp-quote><p>The mean follow-up duration of the cohort since baseline was 9.2 (1.4) years. We added the mean follow-up duration of the cohort in the Materials and methods â Study population section. The electronic linkage with the national health insurance (HI) claim databases started in 2011, which has become an important means of following up. Linkage to local HI databases has been achieved by 97% of the participants since 2014. By December 31 2015, of the all cohort participants, only 4875 (&lt;1%) were lost to follow-up. The diagnosis adjudication has finished for 34,000 reported cases of ischemic heart disease by a review of hospital medical records. Overall, 88% of the diagnoses were confirmed. We have also added this information to the manuscript.</p><disp-quote content-type="editor-comment"><p>6) A major limitation of this study is the dichotomization of health factors, summing the number of factors for each person, then stratifying participants into one of three groups. I appreciate the authors intention to create an aggregate score for âhealth behaviorâ, but used in this context, it is indeed a limitation.</p><p>The HLF used in this study have all been linked with CHD. Dichotomizing them results in substantial loss of information. Summing across these scores then leads to a loss in specificity for the underlying biology. In effect, you may produce a variable that associates with CHD, but does not provide any more biological insight than what we knew over 50 years ago.</p><p>As shown in the supplement, much of the HLF could be driven by adiposity alone. This is after dichotomization, so I would expect even stronger results if the authors used raw BMI or WC. Some of the individual HLF have vastly different association strengths with metabolites, some even in the opposite direction to each other. The aggregate HLF just ends up losing power in this situation and hides the underlying biology. Associations of individual HLF (without dichotomization) provides information that can help improve our understanding of the metabolic consequences of these HLF. The current manuscript is lacking this insight.</p><p>Importantly, mediation analysis is no longer valid when the exposure variable is dichotomized. Causal mediation analysis will suggest a mediation effect even when this is not true. There is no getting around this, unfortunately. Whenever information is removed from the exposure, the putative mediating variable will attempt to explain it.</p></disp-quote><p>Previous studies have examined the association between individual lifestyle related characteristics (without dichotomization) and lipidomic profile separately, including physical activity (2), alcohol consumption (3), BMI (4), and consumption of whole grain, fish and bilberries (5). In our study, we also performed analyses for individual factors (Figure 1âfigure supplement 2-7). Our findings on the associations of lipid metabolites with individual lifestyle related characteristics like physical activity, adiposity, and alcohol consumption were generally consistent with previous studies. We agree with the reviewer that individual HLF may lead to different or even opposite effect on metabolites. Lifestyle related characteristics are also typically correlated with one another. Previous studies suggested that a large proportion of premature death (6) and increased risk of cardiometabolic diseases (7, 8) are attributed to the combination of these unhealthy lifestyles (dichotomized), providing important information on the maximum public health benefit that lifestyle intervention could achieve. A comprehensive analysis of the impact of adopting HLFs on the lipidomic profile is still lacking. Studies are warranted to examine the combined effect on metabolites as the mediators to cardiometabolic diseases. Our study has this unique opportunity to address this important question. Therefore, our main aim was to align with these previously used definitions and provide evidence of the combined effects of lifestyle related characteristics on lipidomic profile.</p><p>We agree with the reviewer that dichotomizing a continuous variable may lose information. A more sophisticated score with appropriated weight might show stronger association. However, a more straightforward definition would be easier to understand and adapted by the public. We have addressed this issue in the Discussion section.</p><p>Regarding the mediation analysis, we agree that when the exposure and mediator are highly correlated and the exposure is dichotomized with losing information, the mediator might show a biased association with the outcome even when it is not. However, this requires a particularly strong association between exposure and mediator. To demonstrate this phenomenon, we picked the strongest exposure-mediator association observed in our study (i.e., BMI-ApoB/ApoA1 with R<sup>2</sup>=0.137). We simulated the data with same sample size and case-control numbers, the same BMI-disease association (effect size OR=1.023) and the same BMI-metabolite association as BMI-ApoB/ApoA1 but no association between metabolite and disease outcome. We designed a series of simulations using different R<sup>2</sup> (0.10â0.99), each repeating 100 times. The simulated data showed as R<sup>2</sup> increases the mediator will have larger bias in association with the outcome (<xref ref-type="fig" rid="respfig1">Author response image 1</xref>), and subsequently larger bias in the corresponding mediation effect (<xref ref-type="fig" rid="respfig2">Author response image 2</xref>).</p><fig id="respfig1"><label>Author response image 1.</label><caption><title>The p value frequency for the association between the mediator and the outcome among the 100 simulations.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60999-resp-fig1-v1.tif"/></fig><fig id="respfig2"><label>Author response image 2.</label><caption><title>The p value frequency for the mediation effect among the 100 simulations.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60999-resp-fig2-v1.tif"/></fig><p><xref ref-type="table" rid="resptable1">Author response table 1</xref> shows the Bonferroni-corrected minimum p value among the 100 simulations. The BMI-metabolite association needs to be increased to R<sup>2</sup>=0.80 to generate a falsely significant mediation effect to achieve Bonferroni-corrected p value &lt; 0.05. This is far from the realistic association between HLFs and metabolite in our study (the strongest R<sup>2</sup>=0.137 for BMI â ApoB/ApoA1). To make a direct comparison, we tested the mediation effect for dichotomized BMI â ApoB/ApoA1 â CHD and the observed mediation p value was less than 2E-16 in our study, far from that would have been biased due to loss of information. We have discussed this issue in the Discussion section.</p><table-wrap id="resptable1" position="float"><label>Author response table 1.</label><caption><title>The Bonferroni-corrected minimum p value in 100 simulations.</title></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Bonferroni-corrected minimum p value for the mediator â outcome association</th><th>Bonferroni-corrected minimum p value for the mediation effect</th></tr></thead><tbody><tr><td>R<sup>2</sup>=0.10</td><td>0.215</td><td>0.227</td></tr><tr><td>R<sup>2</sup>=0.137</td><td>0.258</td><td>0.216</td></tr><tr><td>R<sup>2</sup>=0.15</td><td>0.124</td><td>0.117</td></tr><tr><td>R<sup>2</sup>=0.20</td><td>0.133</td><td>0.189</td></tr><tr><td>R<sup>2</sup>=0.30</td><td>0.114</td><td>0.154</td></tr><tr><td>R<sup>2</sup>=0.40</td><td>0.153</td><td>0.198</td></tr><tr><td>R<sup>2</sup>=0.50</td><td>0.290</td><td>0.234</td></tr><tr><td>R<sup>2</sup>=0.60</td><td>0.217</td><td>0.247</td></tr><tr><td>R<sup>2</sup>=0.70</td><td>0.057</td><td>0.096</td></tr><tr><td>R<sup>2</sup>=0.80</td><td>0.020</td><td>0.047</td></tr><tr><td>R<sup>2</sup>=0.90</td><td>0.014</td><td>0.018</td></tr><tr><td>R<sup>2</sup>=0.99</td><td>0.011</td><td>0.005</td></tr></tbody></table></table-wrap><disp-quote content-type="editor-comment"><p>7) Alcohol consumption appeared to have a complex effect on the lipoprotein profile. From Table 1, around 28.3% of the study population with &gt;= 4 healthy lifestyle factors were considered as moderate alcohol consumers. What was the general distribution of alcohol intake among study population, e.g., non-regular, previous regular, or heavy intake? This information should be given to better understand the effect of alcohol consumption.</p></disp-quote><p>In the present study, around 77.5% of the participants reported drinking less than weekly at baseline. Please find the detailed distribution of alcohol consumption in <xref ref-type="table" rid="resptable2">Author response table 2</xref>.</p><table-wrap id="resptable2" position="anchor"><label>Author response table 2.</label><table frame="hsides" rules="groups"><thead><tr><th/><th>Detailed distribution</th><th>No. of participants</th><th>Percent</th></tr></thead><tbody><tr><td>Non-regular alcohol consumption</td><td>Not regular (less than weekly) drinker</td><td>3,626</td><td>77.5</td></tr><tr><td/><td>Former regular drinker</td><td>205</td><td>4.4</td></tr><tr><td>Moderate alcohol consumption</td><td>Weekly but not daily drinker</td><td>439</td><td>9.4</td></tr><tr><td/><td>Daily drinker with &lt;15g pure alcohol per day</td><td>3</td><td>0.1</td></tr><tr><td/><td>Daily drinker with 15-29g pure alcohol per day</td><td>80</td><td>1.7</td></tr><tr><td>Heavy alcohol consumption</td><td>Daily drinker with 30-59g pure alcohol per day</td><td>120</td><td>2.6</td></tr><tr><td/><td>Daily drinker with â¥60g pure alcohol per day</td><td>208</td><td>4.4</td></tr></tbody></table></table-wrap><disp-quote content-type="editor-comment"><p>8) The authors appear to have attempted a two-factorial analysis of gene scores by the HLF aggregate. It is now known that using the derived scores and an interaction term provides much more power for identifying independence or importance.</p><p>I am not sure why this analysis was performed: &quot;We also examined whether the association between HLFs and lipid metabolites differed by scores of HMGCR, ACLY, or their sum score&quot;. Each genetic variant often has small effect sizes (much smaller than a typical dose of statin). Even the combined score would be very small compared to this. Assuming there isn't some underlying confounding, the inheritance of the genetic variants should be randomly distributed among the population. I do not believe there is any rationale that the association of metabolites with HLF should differ under these conditions.</p></disp-quote><p>Because HLF and statin both have the potential impact on lowering cardiometabolic disease-associated lipids, we performed this analysis to explore the potential joint and interaction effect of HLFs with lipid-lowering drugs on lipid metabolites. Our results demonstrated the independent effect of both HLFs and lipid-lowering drugs on metabolites. Importantly we observed that when simultaneously adjusted in the model, they are targeting different components of the lipidomic profile. Similar to the intuition of the reviewer, we observed HLFs showed no interactions with neither genetic scores (to mimic the effect of HMGCR and ACLY) in its effect on lipid metabolites (Supplementary file 1C-1E). Our results suggest that the pathways affecting LDL and VLDL might be different. We prefer to keep these results to give a comprehensive understanding of the underlying pathway of HLFs and lipid-lowering drugs.</p><disp-quote content-type="editor-comment"><p>9) The authors use the 1000 Genomes reference panel (Phase 3) to impute variants. Is this database (relative dearth of Chinese) appropriate to use for imputing variants in a Chinese population? The authors constructed genetic sores to mimic the effect of statins and ACLY inhibitors based on the Chinese population and also the European population. Use of the genetic scores based on the European population observed similar but weaker associations, especially for some lipid metabolites (small VLDL-TG and LDL-TG) (Supplementary file 1E).</p></disp-quote><p>In our study, we used the 1000 Genomes Project reference panel (Phase 3, all populations) to impute ungenotyped SNPs in the CKB subjects (9, 10). The 1000 Genomes Project Consortium has demonstrated the imputation accuracy using all samples in 1000 Genomes Project as reference to impute other population data, the squared correlation between imputed and experimental genotypes was &gt;95% for common variants in each population (including Chinese) (11). For both the HapMap and the 1000 Genomes Project, it has been a common recommendation that cosmopolitan reference panels be used to improve imputation accuracy for common and low-frequency variants (12, 13). We have provided details of imputation quality of the variants used to construct genetic scores (Supplementary file 1H). It is currently expected that genetic association effects learned from the European population sample are generally less applicable to other populations. Therefore we also developed the genetic score using effects learned from the CKB subjects.</p><p>References</p><p>1. Lloyd-Jones DM, Hong Y, Labarthe D, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Associationâs strategic Impact Goal through 2020 and beyond. Circulation 2010;121:586â613.2. Kujala Urho M., MÃ¤kinen Ville-Petteri, Heinonen Ilkka, et al. Long-term Leisure-time Physical Activity and Serum Metabolome. Circulation 2013;127:340â348.3. WÃ¼rtz P, Cook S, Wang Q, et al. Metabolic profiling of alcohol consumption in 9778 young adults. Int. J. Epidemiol. 2016;45:1493â1506.4. WÃ¼rtz P, Wang Q, Kangas AJ, et al. Metabolic Signatures of Adiposity in Young Adults: Mendelian Randomization Analysis and Effects of Weight Change. PLOS Med. 2014;11:e1001765.5. Lankinen M, Kolehmainen M, JÃ¤Ã¤skelÃ¤inen T, et al. Effects of Whole Grain, Fish and Bilberries on Serum Metabolic Profile and Lipid Transfer Protein Activities: A Randomized Trial (Sysdimet) Berthold HK, editor. PLoS ONE 2014;9:e90352.6. Li Y, Schoufour J, Wang DD, et al. Healthy lifestyle and life expectancy free of cancer, cardiovascular disease, and type 2 diabetes: prospective cohort study. BMJ 2020;368. Available at: https://www.bmj.com/content/368/bmj.l6669. Accessed February 18, 2020.7. Lv J, Yu C, Guo Y, et al. Adherence to a healthy lifestyle and the risk of type 2 diabetes in Chinese adults. Int. J. Epidemiol. 2017;46:1410â1420.8. Lv J, Yu C, Guo Y, et al. Adherence to Healthy Lifestyle and Cardiovascular Diseases in the Chinese Population. J. Am. Coll. Cardiol. 2017;69:1116â1125.9. Dai J, Lv J, Zhu M, et al. Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations. Lancet Respir. Med. 2019;7:881â891.10. Gan W, Bragg F, Walters RG, et al. Genetic Predisposition to Type 2 Diabetes and Risk of Subclinical Atherosclerosis and Cardiovascular Diseases Among 160,000 Chinese Adults. Diabetes 2019;68:2155â2164.11. Anon. A global reference for human genetic variation. Nature 2015;526:68â74.12. Howie B, Marchini J, Stephens M. Genotype Imputation with Thousands of Genomes. G3 Genes Genomes Genet. 2011;1:457â470.13. Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet. Epidemiol. 2010;34:816â834.</p></body></sub-article></article>